var title_f25_29_26064="Tongue sweep";
var content_f25_29_26064=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F54262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F54262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Tongue sweep during laryngoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tongue control during laryngoscopy. A and B) Poor visualization of the cords due to incorrect positioning of the blade. Note how the tongue folds over the blade and obscures the view. C) Correct positioning of the blade to control and move the tongue to the left, providing an optimal view for intubation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Murphy MP, Barker TD, Schneider RE. Endotracheal intubation. In: Manual of Emergency Airway Management, 3rd ed, Walls RM, Murphy MF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_29_26064=[""].join("\n");
var outline_f25_29_26064=null;
var title_f25_29_26065="CUDOS";
var content_f25_29_26065=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F65101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F65101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    CUDOS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 759px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mark Zimmerman, MD. For more information please visit",
"     <a href=\"file://www.outcometracker.org\">",
"      www.outcometracker.org",
"     </a>",
"     . Copyright &copy; 2010. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_29_26065=[""].join("\n");
var outline_f25_29_26065=null;
var title_f25_29_26066="Patient information: Laryngitis (The Basics)";
var content_f25_29_26066=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?6/38/6755\">",
"         Patient information: Laryngeal cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/57/914\">",
"         Patient information: Sore throat in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/26/28066\">",
"         Patient information: Sore throat in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/8/21633\">",
"         Patient information: Spasmodic dysphonia (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?8/34/8738\">",
"         Patient information: Strep throat in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?8/20/8515\">",
"         Patient information: Throat cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?35/15/36082\">",
"         Patient information: Sore throat in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/22/3427\">",
"         Patient information: Sore throat in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Laryngitis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/laryngitis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H262598683\">",
"      <span class=\"h1\">",
"       What is laryngitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Laryngitis is the medical term for when your vocal cords are inflamed. Laryngitis usually causes your voice to sound hoarse and can even make you lose your voice completely.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H262598698\">",
"      <span class=\"h1\">",
"       What causes laryngitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Laryngitis can be caused by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        The common cold and other infections that affect the throat",
"       </li>",
"       <li>",
"        Shouting or straining your voice too much",
"       </li>",
"       <li>",
"        Breathing in harsh chemicals, such as cleaners or gasoline",
"       </li>",
"       <li>",
"        Drinking too much alcohol or smoking a lot",
"       </li>",
"       <li>",
"        Acid reflux, which is when the acid from your stomach leaks into your throat",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      There are also medical problems besides laryngitis that can make your voice hoarse or make you lose your voice. For example, people can have these symptoms because of:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Abnormal growths on the vocal cords",
"       </li>",
"       <li>",
"        Muscle disorders affecting the voice box (such as spasmodic dysphonia)",
"       </li>",
"       <li>",
"        Cancer of the throat",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H262598713\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to get rid of laryngitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. There are different things you can do, depending on what caused your laryngitis.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        If your laryngitis happened because you strained your voice too much, give your voice a rest. If you are a singer or need to use your voice for work, you might want to think about taking voice lessons to learn how to protect your voice.",
"       </li>",
"       <li>",
"        If your laryngitis was caused by smoking or drinking, limit how much you smoke or drink. Better yet, quit smoking completely.",
"       </li>",
"       <li>",
"        If your laryngitis was caused by breathing in a harsh chemical, avoid the chemical. If that is not possible, at least make sure there is a lot fresh air coming in when you are dealing with fumes. If you work near chemical fumes that are making you hoarse, speak with your employer about getting masks or ventilation fans.",
"       </li>",
"       <li>",
"        If your laryngitis was caused by acid reflux, take steps to avoid acid reflux. For example:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Take medicines for acid reflux, if your doctor recommends them.",
"       </li>",
"       <li>",
"        Avoid foods that make your symptoms worse. (Common examples include alcohol, coffee, and chocolate.)",
"       </li>",
"       <li>",
"        Stop smoking, if you smoke.",
"       </li>",
"       <li>",
"        Eat many small meals each day, rather than 2 or 3 big meals.",
"       </li>",
"       <li>",
"        Do not lie down for at least 3 hours after finishing a meal.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H262598728\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on how long your symptoms last and whether you have symptoms besides hoarseness.",
"     </p>",
"     <p>",
"      Most people with laryngitis get better on their own within 2 to 3 weeks. If your voice is hoarse or gone for 2 weeks or longer, and you do not seem to be getting better, see a doctor or nurse.",
"     </p>",
"     <p>",
"      You should also see a doctor or nurse if you have a sore throat and:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You have a fever of at least 101&deg;F or 38.4&deg;C",
"       </li>",
"       <li>",
"        Your throat pain is severe or does not start to improve within 5 to 7 days",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Call 9-1-1 or go to the emergency room if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have trouble breathing",
"       </li>",
"       <li>",
"        Are drooling because you cannot swallow your saliva",
"       </li>",
"       <li>",
"        Have swelling of the neck or tongue",
"       </li>",
"       <li>",
"        Cannot move your neck or have trouble opening your mouth",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H262598743\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. If your doctor or nurse is not sure what is causing your symptoms, you might need tests. For example, you might have a laryngoscopy, which is when the doctor puts a tube with a tiny camera down your throat to look at your voice box.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H262598758\">",
"      <span class=\"h1\">",
"       How is laryngitis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on what is causing it. If your laryngitis is caused by a cold or other minor infection, you might not need treatment. If you do not get better in 2 weeks, there might be something else causing your hoarseness. Other causes of laryngitis are treated on a case-by-case basis.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H262598773\">",
"      <span class=\"h1\">",
"       What if my child gets laryngitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some of the same things that cause laryngitis in adults can cause it children, too. For instance, children can get laryngitis because of a throat infection, because of acid reflux, or because they strain their voice too much. But in children, sounding hoarse can have lots of causes besides laryngitis. For example, children sometimes develop bumps on their vocal cords or have birth defects affecting their voice box.",
"     </p>",
"     <p>",
"      See a doctor or nurse right away if your child has trouble breathing or has pain or other symptoms that seem to be quickly getting worse. You should also see a doctor or nurse of your child has laryngitis for more than 2 weeks, or if the laryngitis is getting worse or is making it hard for your child to interact with others. If your child is a baby, call the baby&rsquo;s doctor as soon as you notice symptoms. The doctor will tell you what to do for your baby.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H262598788\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/26/28066?source=see_link\">",
"       Patient information: Sore throat in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/57/914?source=see_link\">",
"       Patient information: Sore throat in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/34/8738?source=see_link\">",
"       Patient information: Strep throat in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/38/6755?source=see_link\">",
"       Patient information: Laryngeal cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/20/8515?source=see_link\">",
"       Patient information: Throat cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/8/21633?source=see_link\">",
"       Patient information: Spasmodic dysphonia (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/15/36082?source=see_link\">",
"       Patient information: Sore throat in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/22/3427?source=see_link\">",
"       Patient information: Sore throat in children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?25/29/26066?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83524 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-78.134.254.52-C266496ECC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_29_26066=[""].join("\n");
var outline_f25_29_26066=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H262598683\">",
"      What is laryngitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H262598698\">",
"      What causes laryngitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H262598713\">",
"      Is there anything I can do on my own to get rid of laryngitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H262598728\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H262598743\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H262598758\">",
"      How is laryngitis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H262598773\">",
"      What if my child gets laryngitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H262598788\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/38/6755?source=related_link\">",
"      Patient information: Laryngeal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/15/36082?source=related_link\">",
"      Patient information: Sore throat in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/57/914?source=related_link\">",
"      Patient information: Sore throat in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/22/3427?source=related_link\">",
"      Patient information: Sore throat in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/26/28066?source=related_link\">",
"      Patient information: Sore throat in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/8/21633?source=related_link\">",
"      Patient information: Spasmodic dysphonia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/34/8738?source=related_link\">",
"      Patient information: Strep throat in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/20/8515?source=related_link\">",
"      Patient information: Throat cancer (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_29_26067="Erythema migrans bulls eye";
var content_f25_29_26067=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62480%7EPEDS%2F57414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62480%7EPEDS%2F57414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Classic \"bull's eye\" erythema migrans lesion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eugene D Shapiro, MD, FAAP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema migrans lesion with uniform erythema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 300px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythema migrans lesion with uniform erythema. Note that the lesion is not a perfect circle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eugene D Shapiro, MD, FAAP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_29_26067=[""].join("\n");
var outline_f25_29_26067=null;
var title_f25_29_26068="Silver stain lung 1A answer";
var content_f25_29_26068=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F67997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F67997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 569px\">",
"   <div class=\"ttl\">",
"    Pneumocystis carinii",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 549px; height: 227px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Silver-stain of lung tissue from a patient with Pneumocystis carinii pneumonia. Left panel: At low magnification (x200), the alveolar spaces are filled with foamy exudate, which contains small darkly staining cysts forms of P. carinii. Right panel: At higher magnification (x1000), the cysts of P. carinii appear as oval, dark structures against the background.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_29_26068=[""].join("\n");
var outline_f25_29_26068=null;
var title_f25_29_26069="AIDS cholangiopathy";
var content_f25_29_26069=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   AIDS cholangiopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/29/26069/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/29/26069/contributors\">",
"     Nezam H Afdhal, MD, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/29/26069/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/29/26069/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/29/26069/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/29/26069/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/29/26069/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;AIDS cholangiopathy is a syndrome of biliary obstruction resulting from infection-related strictures of the biliary tract [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26069/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. AIDS cholangiopathy occurred in as many as 26 percent of AIDS patients prior to the advent of highly active antiretroviral therapy (HAART) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26069/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]; the current incidence of cholangiopathy is not known, but has decreased in the era of potent antiretroviral therapy (ART) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26069/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The organism most closely associated with AIDS cholangiopathy is Cryptosporidium parvum; other pathogens that have been identified include Microsporidium, cytomegalovirus (CMV), and Cyclospora cayetanensis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26069/abstract/2,6-10\">",
"     2,6-10",
"    </a>",
"    ]. Involvement of the large intrahepatic ducts is usually associated with C. parvum and CMV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26069/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;AIDS cholangiopathy is usually seen in patients with a CD4 count well below",
"    <span class=\"nowrap\">",
"     100/mm3",
"    </span>",
"    and may be their presenting manifestation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26069/abstract/8\">",
"     8",
"    </a>",
"    ]. Affected patients typically present with right upper quadrant and epigastric pain and diarrhea; fever and jaundice are less common, occurring in 10 to 20 percent of patients. The severity of the abdominal pain varies with the biliary tract lesion. Severe abdominal pain is indicative of papillary stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26069/abstract/12\">",
"     12",
"    </a>",
"    ], while milder abdominal pain is usually associated with intrahepatic and extrahepatic sclerosing cholangitis without papillary stenosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58521 \" href=\"UTD.htm?9/44/9935\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The diarrhea in AIDS cholangiopathy is due to small bowel involvement with the infectious agent and may be the initial presenting feature. In one study of 95 patients with diarrhea due to Cryptosporidium, 20 (23 percent) subsequently developed biliary tract disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26069/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13961?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of cryptosporidiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver function tests in AIDS cholangiopathy are usually indicative of cholestasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/50/42790?source=see_link\">",
"     \"Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia\"",
"    </a>",
"    .) In one series, for example, the following findings were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26069/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum gammaglutamyl transpeptidase was persistently elevated in over 90 percent",
"     </li>",
"     <li>",
"      Serum alkaline phosphatase was elevated in 75 percent with a mean level of 700 to 800 int.",
"      <span class=\"nowrap\">",
"       unit/L",
"      </span>",
"     </li>",
"     <li>",
"      Mild increases in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were common",
"     </li>",
"     <li>",
"      Jaundice, when present, was usually mild, with total bilirubin less than twice the upper limit of normal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, all of these tests are normal in some patients (20 percent in one series) despite documented biliary tract abnormalities seen on cholangiography [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26069/abstract/10\">",
"     10",
"    </a>",
"    ]. Furthermore, liver test abnormalities are present in the majority of patients with established AIDS due to opportunistic infections, viral hepatitis, drug hepatotoxicity,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26069/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of AIDS cholangiopathy is usually made by endoscopic retrograde cholangiopancreatography (ERCP). However, other studies can be helpful in early evaluation and in selecting patients for ERCP. Ultrasound is the most cost-effective initial study, with a sensitivity for cholangitis ranging from 75 to 97 percent and specificity of up to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26069/abstract/6,8,16\">",
"     6,8,16",
"    </a>",
"    ]. In one report, 50 patients with suspected AIDS cholangiopathy due to right upper quadrant pain and cholestatic liver function tests were studied with ultrasound and ERCP [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26069/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal ultrasound findings were noted in 18 patients, 17 of whom subsequently had a normal ERCP, while the other patient had changes suggestive of mild cholangiopathy.",
"     </li>",
"     <li>",
"      Of the 32 patients with abnormal findings on ultrasound, all had abnormalities on ERCP: 22 had typical changes of cholangiopathy; and 10 had a variety of other conditions including pancreatitis, biliary calculi, and AIDS-related lymphoma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, ERCP is the recommended procedure in the patient with suspected AIDS cholangiopathy and a positive ultrasound. It allows confirmation of the diagnosis and the performance of therapeutic procedures, if indicated. Biliary brushings and biopsy, biliary aspiration, and small bowel biopsy can also be performed to aid in diagnosis. This includes detection of the etiologic agent using appropriate stains.",
"   </p>",
"   <p>",
"    As noted above, the likelihood of finding anatomic abnormalities at ERCP in the patient with a negative ultrasound is small [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26069/abstract/16\">",
"     16",
"    </a>",
"    ]. However, ERCP is indicated in this setting if the patient has symptoms suggestive of papillary stenosis, particularly severe abdominal pain, or known Cryptosporidium or CMV infection.",
"   </p>",
"   <p>",
"    Cholangiography reveals one of four patterns [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26069/abstract/2,6,8,11,17\">",
"     2,6,8,11,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Combined papillary stenosis and sclerosing cholangitis &ndash; 50 to 60 percent",
"     </li>",
"     <li>",
"      Combined intrahepatic and extrahepatic sclerosing cholangitis without papillary stenosis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef58521 \" href=\"UTD.htm?9/44/9935\">",
"       image 1",
"      </a>",
"      ) &ndash; 20 percent or less",
"     </li>",
"     <li>",
"      Papillary stenosis alone &ndash; 10 percent",
"     </li>",
"     <li>",
"      Long extrahepatic bile duct stricture with or without intrahepatic sclerosing cholangitis is unusual",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The combination of papillary stenosis and intrahepatic ductal strictures appears relatively unique to AIDS cholangiopathy; this combination is not found in primary sclerosing cholangitis. In patients with papillary stenosis, pancreatic abnormalities (such as pancreatic duct dilatation) are frequently seen with pancreatograms and may be responsible for some of the abdominal pain [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26069/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other imaging studies are occasionally useful in patients with possible AIDS cholangiopathy to exclude other possible causes of abnormal liver tests. Computed tomography (CT) is helpful in jaundiced patients to look for intrahepatic masses, abdominal adenopathy, pancreatic disease and gallbladder and biliary abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26069/abstract/15\">",
"     15",
"    </a>",
"    ]. A hepatobiliary imino-diacetic acid (HIDA) scan may show delayed excretion of the tracer, suggesting biliary obstruction, or may demonstrate focal biliary strictures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26069/abstract/18\">",
"     18",
"    </a>",
"    ]. Magnetic resonance cholangiopancreatography has not been well studied in patients with AIDS cholangiopathy but can probably provide similar information as ultrasonography [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26069/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although infection is the most common cause of AIDS cholangiopathy, medical treatment directed against C. parvum, Microsporidium, or CMV does not influence symptoms or cholangiographic abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26069/abstract/10,11,13\">",
"     10,11,13",
"    </a>",
"    ]. The therapy of AIDS cholangiopathy is primarily endoscopic, and the approach varies with the anatomic abnormality.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who have abdominal pain, cholangitis, or jaundice associated with papillary stenosis show marked symptomatic relief after sphincterotomy. The relief can be long-lasting; the frequency with which this occurs has varied from 23 percent to 70 to 100 percent in different studies [",
"      <a class=\"abstract\" href=\"UTD.htm?25/29/26069/abstract/2,6,11,12,15\">",
"       2,6,11,12,15",
"      </a>",
"      ]. However, serum alkaline phosphatase concentrations are stable or may continue to rise, a probable reflection of progression of intrahepatic disease [",
"      <a class=\"abstract\" href=\"UTD.htm?25/29/26069/abstract/10,12\">",
"       10,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Isolated or dominant common bile duct strictures can be treated with endoscopic stenting. Sphincterotomy does not help patients with sclerosing cholangitis in the absence of papillary stenosis. Treatment options for patients with intrahepatic or extrahepatic sclerosing cholangitis are limited.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     Ursodeoxycholic acid",
"    </a>",
"    (UDCA) has been used in the treatment of primary sclerosing cholangitis, a disorder with similar intrahepatic changes to AIDS cholangiopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41097?source=see_link\">",
"     \"Treatment of primary sclerosing cholangitis\"",
"    </a>",
"    .) This observation has led to its experimental use in patients with AIDS cholangiopathy; results in a small number of patients have found an improvement in symptoms and a fall in serum alkaline phosphatase and gammaglutamyl transpeptidase [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26069/abstract/20\">",
"     20",
"    </a>",
"    ]. We suggest giving UDCA in a dose 300 mg three times daily, primarily in patients who have intrahepatic ductal disease and markedly elevated liver tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The survival of patients is not affected by cholangiopathy, since the mortality rate is primarily determined by the natural history of AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26069/abstract/2,8,10\">",
"     2,8,10",
"    </a>",
"    ]. An isolated report described the development of cholangiocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26069/abstract/21\">",
"     21",
"    </a>",
"    ]. Because cholangiopathy typically occurs in patients with advanced AIDS (CD4 cell count below",
"    <span class=\"nowrap\">",
"     100/mm3)",
"    </span>",
"    the mean survival has been only 7 to 12 months. In one series of 45 patients, for example, one- and two-year survival rates were 41 and 8 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26069/abstract/2\">",
"     2",
"    </a>",
"    ]. In a retrospective study of 82 AIDS patients who developed cryptosporidiosis from contaminated water in Milwaukee, those who had biliary symptoms were significantly more likely to die than HIV-infected patients without these symptoms during the following year (83 versus 48 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26069/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, these studies were performed prior to the availability of potent antiretroviral therapy (ART). The use of ART has a definite benefit in the treatment of enteric infections due to Cryptosporidium or Microsporidium; it is not known if this type of aggressive treatment will also favorably effect the outcome of AIDS cholangiopathy. As noted above, it appears that the incidence of AIDS cholangiopathy has declined since the Introduction of ART. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16089?source=see_link\">",
"     \"Microsporidiosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13961?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of cryptosporidiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AIDS cholangiopathy is a syndrome of biliary obstruction resulting from infection-associated strictures of the biliary tract, usually seen in patients with a CD4 count well below",
"      <span class=\"nowrap\">",
"       100/mm3.",
"      </span>",
"      The incidence is not known precisely but has declined substantially after the introduction of potent antiretroviral therapy in the mid-1990s.",
"     </li>",
"     <li>",
"      C. parvum is the most common pathogen associated with this disorder, but CMV, Microsporidium, and Cyclospora have also been identified. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients typically have right upper quadrant and epigastric pain, and diarrhea; fever and jaundice are less common. The severity of the abdominal pain varies with the biliary tract lesion. Severe abdominal pain is indicative of papillary stenosis, while milder abdominal pain is usually associated with intrahepatic and extrahepatic sclerosing cholangitis without papillary stenosis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef58521 \" href=\"UTD.htm?9/44/9935\">",
"       image 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is made by ERCP. However, other studies (particularly ultrasound and MRCP) can be helpful in early evaluation and in selecting patients for ERCP. The large intrahepatic ducts are most frequently involved with C. parvum and CMV infection. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although infection is the most common cause of AIDS cholangiopathy, medical treatment directed against C. parvum, Microsporidium, or CMV does not influence symptoms or cholangiographic abnormalities. Thus, treatment of the cholangiographic abnormalities is primarily endoscopic, and the approach varies with the anatomic abnormality.",
"     </li>",
"     <li>",
"      In patients who have abdominal pain, cholangitis, or jaundice associated with papillary stenosis, we suggest sphincterotomy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Sphincterotomy does not help patients with sclerosing cholangitis in the absence of papillary stenosis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with an isolated or dominant common bile duct stricture we suggest endoscopic stenting (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment options for patients with intrahepatic or extrahepatic sclerosing cholangitis are limited. We suggest giving UDCA in a dose 300 mg three times daily, primarily in patients who have intrahepatic ductal disease and markedly elevated liver function tests (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The survival of patients is not affected by cholangiopathy, since the mortality rate is primarily determined by the natural history of AIDS. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26069/abstract/1\">",
"      Margulis SJ, Honig CL, Soave R, et al. Biliary tract obstruction in the acquired immunodeficiency syndrome. Ann Intern Med 1986; 105:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26069/abstract/2\">",
"      Ducreux M, Buffet C, Lamy P, et al. Diagnosis and prognosis of AIDS-related cholangitis. AIDS 1995; 9:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26069/abstract/3\">",
"      Chen XM, LaRusso NF. Cryptosporidiosis and the pathogenesis of AIDS-cholangiopathy. Semin Liver Dis 2002; 22:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26069/abstract/4\">",
"      Vakil NB, Schwartz SM, Buggy BP, et al. Biliary cryptosporidiosis in HIV-infected people after the waterborne outbreak of cryptosporidiosis in Milwaukee. N Engl J Med 1996; 334:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26069/abstract/5\">",
"      Chen XM, Keithly JS, Paya CV, LaRusso NF. Cryptosporidiosis. N Engl J Med 2002; 346:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26069/abstract/6\">",
"      Cello JP. Acquired immunodeficiency syndrome cholangiopathy: spectrum of disease. Am J Med 1989; 86:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26069/abstract/7\">",
"      Teixidor HS, Godwin TA, Ramirez EA. Cryptosporidiosis of the biliary tract in AIDS. Radiology 1991; 180:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26069/abstract/8\">",
"      Bouche H, Housset C, Dumont JL, et al. AIDS-related cholangitis: diagnostic features and course in 15 patients. J Hepatol 1993; 17:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26069/abstract/9\">",
"      Liberman E, Yen TS. Foamy macrophages in acquired immunodeficiency syndrome cholangiopathy with Encephalitozoon intestinalis. Arch Pathol Lab Med 1997; 121:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26069/abstract/10\">",
"      Forbes A, Blanshard C, Gazzard B. Natural history of AIDS related sclerosing cholangitis: a study of 20 cases. Gut 1993; 34:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26069/abstract/11\">",
"      Benhamou Y, Caumes E, Gerosa Y, et al. AIDS-related cholangiopathy. Critical analysis of a prospective series of 26 patients. Dig Dis Sci 1993; 38:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26069/abstract/12\">",
"      Cello JP, Chan MF. Long-term follow-up of endoscopic retrograde cholangiopancreatography sphincterotomy for patients with acquired immune deficiency syndrome papillary stenosis. Am J Med 1995; 99:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26069/abstract/13\">",
"      Hashmey R, Smith NH, Cron S, et al. Cryptosporidiosis in Houston, Texas. A report of 95 cases. Medicine (Baltimore) 1997; 76:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26069/abstract/14\">",
"      Lefkowitch JH. The liver in AIDS. Semin Liver Dis 1997; 17:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26069/abstract/15\">",
"      Chalasani N, Wilcox CM. Etiology, evaluation, and outcome of jaundice in patients with acquired immunodeficiency syndrome. Hepatology 1996; 23:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26069/abstract/16\">",
"      Daly CA, Padley SP. Sonographic prediction of a normal or abnormal ERCP in suspected AIDS related sclerosing cholangitis. Clin Radiol 1996; 51:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26069/abstract/17\">",
"      Teare JP, Daly CA, Rodgers C, et al. Pancreatic abnormalities and AIDS related sclerosing cholangitis. Genitourin Med 1997; 73:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26069/abstract/18\">",
"      Brunetti JC, Van Heertum RL, Kempf JS, et al. Tc-99m DISIDA hepatobiliary scintigraphy in AIDS cholangitis. Clin Nucl Med 1994; 19:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26069/abstract/19\">",
"      Bilgin M, Balci NC, Erdogan A, et al. Hepatobiliary and pancreatic MRI and MRCP findings in patients with HIV infection. AJR Am J Roentgenol 2008; 191:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26069/abstract/20\">",
"      Castiella A, Iribarren JA, L&oacute;pez P, et al. Ursodeoxycholic acid in the treatment of AIDS-associated cholangiopathy. Am J Med 1997; 103:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26069/abstract/21\">",
"      Hocqueloux L, Gervais A. Cholangiocarcinoma and AIDS-related sclerosing cholangitis. Ann Intern Med 2000; 132:1006.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 667 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-CCB85E928E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_29_26069=[""].join("\n");
var outline_f25_29_26069=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/667\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/667|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/44/9935\" title=\"diagnostic image 1\">",
"      Cryptosporidium cholangitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/50/42790?source=related_link\">",
"      Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13961?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of cryptosporidiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16089?source=related_link\">",
"      Microsporidiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41097?source=related_link\">",
"      Treatment of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_29_26070="Management of stage I nonseminomatous germ cell tumors";
var content_f25_29_26070=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of stage I nonseminomatous germ cell tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/29/26070/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/29/26070/contributors\">",
"     Timothy D Gilligan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/29/26070/contributors\">",
"     Philip W Kantoff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/29/26070/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/29/26070/contributors\">",
"     William K Oh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/29/26070/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/29/26070/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/29/26070/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testicular cancers, the majority of which are germ cell tumors (GCTs), are one of the most curable solid neoplasms with a five-year survival rate of over 95 percent. Testicular cancer accounts for approximately 200 to 800 cases per 100,000 men worldwide with fewer than 350 deaths per 100,000 men each year [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26070/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Testicular GCTs are more sensitive to systemic chemotherapy than most adult solid tumors. As a result, chemotherapy is the standard treatment for men with advanced seminoma or nonseminomatous germ cell tumors (NSGCTs) and for those with persistently elevated serum tumor markers following orchiectomy. The success of chemotherapy in advanced disease has led to its use in selected men with stage I and II disease.",
"   </p>",
"   <p>",
"    The management of men with stage I NSGCT following orchiectomy, including the choice between adjuvant chemotherapy, retroperitoneal lymph node dissection (RPLND), and active surveillance will be reviewed here. The management of men with stage II NSGCT and a general overview of the management of testicular GCTs are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/19/10550?source=see_link\">",
"     \"Management of stage II nonseminomatous germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=see_link\">",
"     \"Overview of the treatment of testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;With only rare exceptions in men who present with disseminated disease, all men with testicular cancer undergo a radical inguinal orchiectomy for diagnosis and initial treatment. If radiographic imaging studies are negative and serum tumor markers post-orchiectomy are normal, patients are defined as having clinical stage I nonseminomatous germ cell tumor (NSGCT, (",
"    <a class=\"graphic graphic_table graphicRef82117 \" href=\"UTD.htm?35/13/36061\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef56341 \" href=\"UTD.htm?20/34/21037\">",
"     table 2",
"    </a>",
"    )). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=see_link\">",
"     \"Overview of the treatment of testicular germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/63/33782?source=see_link&amp;anchor=H2#H2\">",
"     \"Radical inguinal orchiectomy for testicular germ cell tumors\", section on 'Surgical treatment of the testis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors\", section on 'CT scan'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of clinical stage I NSGCTs are cured with orchiectomy alone and do not require further treatment. However, it is difficult to identify which patients with stage I NSGCT are at highest risk for recurrence and may be the most likely to benefit from adjuvant treatment. While treatment immediately following orchiectomy can reduce the risk of relapse, it represents overtreatment for most patients. In addition, although the risk of recurrence is approximately 30 percent for men undergoing surveillance, treatment at the time of recurrence is almost always curative.",
"   </p>",
"   <p>",
"    Men with persistently elevated post-orchiectomy serum tumor markers and normal imaging studies are defined as having clinical stage Is disease. Persistently elevated markers generally indicate the presence of metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26070/abstract/2\">",
"     2",
"    </a>",
"    ]. Therefore, these patients should be treated similarly to men with stage III disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H178160589\">",
"    <span class=\"h1\">",
"     RISK STRATIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous attempts have been made to identify men with clinical stage I nonseminomatous germ cell tumors (NSGCTs) at high risk for relapse and thus most likely to benefit from post-orchiectomy treatment. The most widely used risk factors for recurrence in men undergoing surveillance following orchiectomy for clinical stage I disease include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26070/abstract/3-8\">",
"     3-8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lymphovascular invasion (LVI)",
"     </li>",
"     <li>",
"      Predominance of an embryonal component in the primary tumor",
"     </li>",
"     <li>",
"      Pathologic tumor stage above T2 (",
"      <a class=\"graphic graphic_table graphicRef82117 \" href=\"UTD.htm?35/13/36061\">",
"       table 1",
"      </a>",
"      )&nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Men with testicular NSGCT and none of these factors have",
"    <strong>",
"     low-risk disease",
"    </strong>",
"    . The presence of one or more of these factors denotes",
"    <strong>",
"     high-risk disease",
"    </strong>",
"    .",
"   </p>",
"   <p>",
"    In several studies, the presence of LVI alone or LVI plus embryonal carcinoma predominance is associated with a 40 to 55 percent relapse rate [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26070/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In contrast, the relapse rate in men without these factors is 10 to 14 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26070/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40926142\">",
"    <span class=\"h1\">",
"     TREATMENT APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveillance, adjuvant chemotherapy, and retroperitoneal lymph node dissection (RPLND) are therapeutic options for men with clinical stage I nonseminomatous germ cell tumors (NSGCTs). Each approach is associated with a 98 percent rate of long-term, disease-specific survival.",
"   </p>",
"   <p>",
"    The approach to management depends upon various factors, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The likelihood of relapse (based on presence of low- versus high-risk disease characteristics)",
"     </li>",
"     <li>",
"      The relative importance of different toxicities for an individual patient",
"     </li>",
"     <li>",
"      The ability of a patient to adhere to posttreatment surveillance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For men who are interested in fertility preservation, sperm banking should be performed prior to treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40926150\">",
"    <span class=\"h2\">",
"     Low-risk disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men with low-risk disease, we recommend active surveillance rather than RPLND or adjuvant chemotherapy. These men have an excellent prognosis and surveillance avoids the complications of RPLND and toxicity of chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26070/abstract/7,9,10\">",
"     7,9,10",
"    </a>",
"    ]. &nbsp;(See",
"    <a class=\"local\" href=\"#H178160589\">",
"     'Risk stratification'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3334?source=see_link\">",
"     \"Active surveillance following orchiectomy for stage I testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence supporting this approach comes from the Swedish and Norwegian Testicular Cancer Project (SWENOTECA) Management Program [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26070/abstract/7\">",
"     7",
"    </a>",
"    ]. Between 1998 and 2005, 745 men in Sweden and Norway were treated prospectively for clinical stage I NSGCT. Active surveillance was recommended for men without LVI (n=491), although they were allowed to choose adjuvant chemotherapy. At a median follow-up of 4.7 years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The relapse rate was higher among men who underwent surveillance rather than chemotherapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      [BEP]) (12 versus 1.3 percent with one cycle of BEP or 0 percent with two cycles of BEP).",
"     </li>",
"     <li>",
"      Overall mortality rate was only one percent, and none of these deaths were due to progressive testicular cancer.",
"     </li>",
"     <li>",
"      The long-term cure rate for the entire cohort was 85 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The SWENOTECA results for men with high-risk disease are discussed below. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Active surveillance'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Similar results were reported from the British Columbia Cancer Agency and the Oregon Testis Cancer Program (n=233 men) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26070/abstract/9\">",
"     9",
"    </a>",
"    ]. The relapse rate during surveillance was 10 percent among those who had neither LVI nor a predominancy of embryonal carcinoma, 13 percent among those whose tumors had LVI, and about 20 percent among those who had a predominance of embryonal carcinoma but no LVI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26070/abstract/9\">",
"     9",
"    </a>",
"    ]. However, no deaths from testicular cancer were reported. With a median follow-up of 52 months, 88 and 98 percent of relapses occurred during the first two years and three years, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40926158\">",
"    <span class=\"h2\">",
"     High-risk disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men with high-risk disease, active surveillance or adjuvant chemotherapy are equally reasonable options. The decision of which modality to use should be based on patient preference: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For some men who choose a more aggressive course of action, we suggest adjuvant chemotherapy. For these men, the opportunity to be treated immediately with a short course of chemotherapy is preferable to facing an almost 40 percent chance of recurrence at an unpredictable time in the future, which would require a longer course of treatment. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Adjuvant chemotherapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For men who choose treatment but prefer not to undergo adjuvant chemotherapy, RPLND is an appropriate alternative provided the technical expertise is available. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9272?source=see_link&amp;anchor=H12#H12\">",
"       \"Retroperitoneal lymph node dissection in testicular germ cell tumors\", section on 'Stage I and II GCT'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For men who prefer not to undergo adjuvant treatment and understand that they have up to a 40 percent risk of relapse, active surveillance is appropriate. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3334?source=see_link&amp;anchor=H900676917#H900676917\">",
"       \"Active surveillance following orchiectomy for stage I testicular germ cell tumors\", section on 'Active surveillance protocols'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Adjuvant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men with stage I NSGCT who select adjuvant chemotherapy, we administer one to two courses of adjuvant platinum-based chemotherapy (eg, BEP (",
"    <a class=\"graphic graphic_table graphicRef65516 \" href=\"UTD.htm?14/2/14382\">",
"     table 3",
"    </a>",
"    )). The use of adjuvant chemotherapy is supported by a trial conducted by the German Testicular Cancer Study group where 382 men with clinical stage I NSGCT were randomly assigned treatment with either one cycle of chemotherapy with BEP or to RPLND [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26070/abstract/11\">",
"     11",
"    </a>",
"    ]. At a median follow-up of 4.7 years, adjuvant chemotherapy resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significantly lower rate of recurrence compared to RPLND (2 versus 15)",
"     </li>",
"     <li>",
"      An improvement in the two-year recurrence-free survival rate (100 versus 92 percent, hazard ratio [HR] 7.9, 95% CI 1.8-34.5)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All patients who relapsed were successfully retreated, and there were no deaths due to testicular cancer.",
"   </p>",
"   <p>",
"    The benefit of chemotherapy seen in this randomized trial is supported a review of the data from available published nonrandomized studies, performed by the authors of this topic [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26070/abstract/8,12-20\">",
"     8,12-20",
"    </a>",
"    ]. Among 655 men who received adjuvant chemotherapy for clinical stage I disease, there were only 16 relapses (2.4 percent), which occurred at a median follow-up ranging from 31 to 113 months. There were only seven cancer-related deaths identified (1 percent).",
"   </p>",
"   <p>",
"    The administration of up to two courses of platinum-based chemotherapy has minimized concerns of acute and delayed side effects of treatment (including a lowered risk of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -induced pulmonary toxicity), which are generally seen when four or more cycles are administered. There is also evidence that limiting the exposure to chemotherapy reduces the risk that men will become infertile [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26070/abstract/12,13,21\">",
"     12,13,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20250?source=see_link\">",
"     \"Treatment-related toxicity in men with testicular germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/41/16025?source=see_link\">",
"     \"Approach to the care of long-term testicular cancer survivors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8532060\">",
"    <span class=\"h3\">",
"     Retroperitoneal lymph node dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;RPLND remains a reasonable alternative to chemotherapy, provided the technical expertise is available (ie, surgeons who perform at least 24 procedures annually) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26070/abstract/3\">",
"     3",
"    </a>",
"    ]. Unfortunately, very few centers have extensive experience with RPLND, and the effectiveness and safety of RPLND in less experienced hands may be compromised [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26070/abstract/9\">",
"     9",
"    </a>",
"    ]. In the German Testicular Cancer Study discussed above, 7 of the 15 patients (47 percent) who underwent RPLND had recurrent retroperitoneal disease, which may reflect a lack of experience in performing an RPLND [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26070/abstract/11\">",
"     11",
"    </a>",
"    ]. This high rate of relapse underscores the importance of maintaining quality outside of centers with extensive experience. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9272?source=see_link\">",
"     \"Retroperitoneal lymph node dissection in testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When performed by experienced surgeons, RPLND is safe, with essentially no mortality and an extremely low rate of ejaculatory dysfunction or other long-term morbidity. In addition, the use of RPLND substantially reduces the number of men who ultimately receive chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9272?source=see_link&amp;anchor=H12#H12\">",
"     \"Retroperitoneal lymph node dissection in testicular germ cell tumors\", section on 'Stage I and II GCT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although RPLND is an alternative to adjuvant chemotherapy or surveillance following orchiectomy, men should be aware that chemotherapy may still be required after RPLND. Among patients managed with RPLND, 20 percent are likely to be upstaged at final pathology and will undergo adjuvant chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/19/10550?source=see_link&amp;anchor=H2#H2\">",
"     \"Management of stage II nonseminomatous germ cell tumors\", section on 'Pathologic stage II NSGCT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While RPLND plus two cycles of chemotherapy results in the lowest reported relapse rate (about 1 percent), most experts do not recommend this approach given that men have a 99 percent long-term survival rate with either RPLND or adjuvant chemotherapy (as single modality treatment). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Active surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials that compare adjuvant chemotherapy or RPLND with active surveillance in men with stage I NSGCT. The safety of surveillance among men with clinical stage I NSGCT was shown in a study of 223 men (27 percent had LVI, 49 percent had embryonal carcinoma predominant tumors, and 17 percent had both LVI and EC predominance) followed at either the British Columbia Cancer Agency or the Oregon Testis Cancer Program [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26070/abstract/9\">",
"     9",
"    </a>",
"    ]. After a median follow-up of over four years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disease-specific survival was almost 100 percent.",
"     </li>",
"     <li>",
"      The relapse rate was 26 percent overall: 14 percent among those with lymphovascular invasion alone, 37 percent among those with LVI and embryonal carcinoma predominance, and 18 percent among those with EC predominance but no LVI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the high rate of relapse, all but one patient had good risk disease at relapse and only 17 (8 percent) required postchemotherapy resection of residual masses. No patients required second line chemotherapy. &nbsp;",
"   </p>",
"   <p>",
"    One factor that must be taken into account if placing high-risk patients on surveillance, however, is the psychological stress of worrying about relapse and the potential psychological trauma to the patient if relapse occurs and his life must be put on hold on short notice and at an unpredictable time. One appeal of adjuvant chemotherapy after orchiectomy is the near certainty it provides that the disease has been cured, particularly in this high-risk group.",
"   </p>",
"   <p>",
"    Additional data suggesting that adjuvant chemotherapy is preferable to active surveillance come from the SWENOTECA Management Program. Men with LVI present (n=227) were recommended for one cycle of BEP (although they could choose active surveillance or two total cycles) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26070/abstract/7\">",
"     7",
"    </a>",
"    ]. The relapse rate was higher among men managed with surveillance compared with one- or two-cycles of BEP adjuvant chemotherapy (13 versus 2 and 0 percent, respectively). However, there were no relapses among the 70 patients who chose to receive two cycles of BEP [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26070/abstract/7\">",
"     7",
"    </a>",
"    ]. Still, the mortality rate in the entire cohort was one percent (n=8 deaths), none of which were from progressive disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The effectiveness of systemic chemotherapy for advanced or metastatic testicular germ cell tumors (GCTs) has led to its integration into the management of patients with early stage disease. The goal of therapy is to reduce the likelihood of relapse and minimize overtreatment and treatment-related toxicity. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most widely evaluated histologic risk factors for recurrence in men undergoing surveillance following orchiectomy for clinical stage I disease include the presence of lymphovascular invasion, predominance of an embryonal carcinoma component, and tumor stage above T2. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Men are at",
"      <strong>",
"       low-risk",
"      </strong>",
"      if they have none of these risk factors.",
"     </li>",
"     <li>",
"      Men are at",
"      <strong>",
"       high-risk",
"      </strong>",
"      if one or more of these factors are present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men with low-risk disease, we recommend surveillance rather than adjuvant therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For men who decline surveillance or are not good candidates for surveillance, we suggest adjuvant chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <strong>",
"      </strong>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (BEP) for one to two cycles (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H40926150\">",
"       'Low-risk disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For men with high-risk disease and desire an aggressive course of action, we suggest adjuvant chemotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Adjuvant chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For men who prefer not to undergo adjuvant chemotherapy, a retroperitoneal lymph node dissection (RPLND) is an appropriate alternative provided the technical expertise is available. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9272?source=see_link&amp;anchor=H12#H12\">",
"       \"Retroperitoneal lymph node dissection in testicular germ cell tumors\", section on 'Stage I and II GCT'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For men who prefer not to undergo adjuvant treatment and understand that they have up to a 40 percent risk of relapse, active surveillance is reasonable. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3334?source=see_link&amp;anchor=H900676917#H900676917\">",
"       \"Active surveillance following orchiectomy for stage I testicular germ cell tumors\", section on 'Active surveillance protocols'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rosen Am, Drazer MW, Eggener SE. Global trends in testicular cancer incidence and mortality. 2010 Genitourinary Cancers Symposium. Abstr 259.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26070/abstract/2\">",
"      Klepp O, Flodgren P, Maartman-Moe H, et al. Early clinical stages (CS1, CS1Mk+ and CS2A) of non-seminomatous testis cancer. Value of pre- and post-orchiectomy serum tumor marker information in prediction of retroperitoneal lymph node metastases. Swedish-Norwegian Testicular Cancer Project (SWENOTECA). Ann Oncol 1990; 1:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26070/abstract/3\">",
"      Stephenson AJ, Sheinfeld J. Management of patients with low-stage nonseminomatous germ cell testicular cancer. Curr Treat Options Oncol 2005; 6:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26070/abstract/4\">",
"      Pectasides D, Pectasides E, Constantinidou A, Aravantinos G. Current management of stage I testicular non-seminomatous germ cell tumours. Crit Rev Oncol Hematol 2009; 70:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26070/abstract/5\">",
"      Hermans BP, Sweeney CJ, Foster RS, et al. Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection. J Urol 2000; 163:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26070/abstract/6\">",
"      Pohar KS, Rabbani F, Bosl GJ, et al. Results of retroperitoneal lymph node dissection for clinical stage I and II pure embryonal carcinoma of the testis. J Urol 2003; 170:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26070/abstract/7\">",
"      Tandstad T, Dahl O, Cohn-Cedermark G, et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol 2009; 27:2122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26070/abstract/8\">",
"      Dearnaley DP, Fossa SD, Kaye SB, et al. Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17). Br J Cancer 2005; 92:2107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26070/abstract/9\">",
"      Kollmannsberger C, Moore C, Chi KN, et al. Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. Ann Oncol 2010; 21:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26070/abstract/10\">",
"      Sturgeon JF, Moore MJ, Kakiashvili DM, et al. Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience. Eur Urol 2011; 59:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26070/abstract/11\">",
"      Albers P, Siener R, Krege S, et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 2008; 26:2966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26070/abstract/12\">",
"      Pont J, Albrecht W, Postner G, et al. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 1996; 14:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26070/abstract/13\">",
"      Cullen MH, Stenning SP, Parkinson MC, et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol 1996; 14:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26070/abstract/14\">",
"      B&ouml;hlen D, Borner M, Sonntag RW, et al. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J Urol 1999; 161:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26070/abstract/15\">",
"      Oliver RT, Ong J, Shamash J, et al. Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy. Urology 2004; 63:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26070/abstract/16\">",
"      Oliver RT, Raja MA, Ong J, Gallagher CJ. Pilot study to evaluate impact of a policy of adjuvant chemotherapy for high risk stage 1 malignant teratoma on overall relapse rate of stage 1 cancer patients. J Urol 1992; 148:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26070/abstract/17\">",
"      Abratt RP, Pontin AR, Barnes RD, Reddi BV. Adjuvant chemotherapy for stage I non-seminomatous testicular cancer. S Afr Med J 1994; 84:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26070/abstract/18\">",
"      Ondrus D, Goncalves F, Kausitz J, et al. The value of prognostic factors in the management of stage I nonseminomatous germ cell testicular tumors (NSGCTT). Neoplasma 1996; 43:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26070/abstract/19\">",
"      Chevreau, C, Soulie, M, Rischmann, P, et al. Adjuvant chemotherapy in high risk stage I non-seminomatous germ cell tumors (abstract). Proc Am Soc Clin Oncol 1997; 16:320a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26070/abstract/20\">",
"      Amato RJ, Ro JY, Ayala AG, Swanson DA. Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis. Urology 2004; 63:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26070/abstract/21\">",
"      B&ouml;hlen D, Burkhard FC, Mills R, et al. Fertility and sexual function following orchiectomy and 2 cycles of chemotherapy for stage I high risk nonseminomatous germ cell cancer. J Urol 2001; 165:441.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2951 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-198.199.123.20-28C064E6EE-14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_29_26070=[""].join("\n");
var outline_f25_29_26070=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H178160589\">",
"      RISK STRATIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40926142\">",
"      TREATMENT APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40926150\">",
"      Low-risk disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40926158\">",
"      High-risk disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Adjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8532060\">",
"      - Retroperitoneal lymph node dissection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Active surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2951\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2951|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/13/36061\" title=\"table 1\">",
"      TNM staging testicular CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/34/21037\" title=\"table 2\">",
"      Stage group testicular CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/2/14382\" title=\"table 3\">",
"      Bleomycin etoposide and cisplatin regimen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3334?source=related_link\">",
"      Active surveillance following orchiectomy for stage I testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/41/16025?source=related_link\">",
"      Approach to the care of long-term testicular cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=related_link\">",
"      Initial risk-stratified treatment for advanced testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/19/10550?source=related_link\">",
"      Management of stage II nonseminomatous germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=related_link\">",
"      Overview of the treatment of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/63/33782?source=related_link\">",
"      Radical inguinal orchiectomy for testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9272?source=related_link\">",
"      Retroperitoneal lymph node dissection in testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20250?source=related_link\">",
"      Treatment-related toxicity in men with testicular germ cell tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_29_26071="Buprenorphine: Pediatric drug information";
var content_f25_29_26071=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Buprenorphine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"    see \"Buprenorphine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?42/30/43494?source=see_link\">",
"    see \"Buprenorphine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F11370705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F143056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Buprenex&reg;;",
"     </li>",
"     <li>",
"      Butrans&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F143057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Butrans&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1051379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Narcotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Opioid Partial Agonist",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1051372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"      see \"Buprenorphine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Dose should be titrated to appropriate effect.",
"     </b>",
"     Use",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     of the dose listed in patients with pre-existing respiratory depression, decreased respiratory reserve, hypoxia, hypercapnia, significant COPD, or cor pulmonale, and in those receiving medications with CNS or respiratory depressant effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Moderate to severe pain:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-12 years: I.M., slow I.V. injection: 2-6 mcg/kg every 4-6 hours;",
"     <b>",
"      Note:",
"     </b>",
"     3 mcg/kg/dose has been most commonly studied; not all children have faster clearance rates than adults; some children may require dosing intervals of every 6-8 hours; observe clinical effects to establish the proper dosing interval",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;13 years and Adults: I.M., slow I.V. injection: Initial: Opiate-naive: 0.3 mg every 6-8 hours as needed; initial dose (up to 0.3 mg) may be repeated once in 30-60 minutes if clinically needed;",
"     <b>",
"      Note:",
"     </b>",
"     In adults, single doses of up to 0.6 mg administered I.M. may occasionally be required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Opioid dependence:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Do not start induction with buprenorphine until objective and clear signs of withdrawal are apparent (otherwise withdrawal may be precipitated). Children &ge;16 years and Adults: Sublingual:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Induction: Target range: 12-16 mg/day (doses during one induction study used 8 mg on day 1, followed by 16 mg on day 2; other studies accomplished induction over 3-4 days). Treatment should begin at least 4 hours after last use of heroin or short-acting opioid, preferably when first signs of withdrawal appear. Titrating dose to clinical effect should be done as rapidly as possible to prevent undue withdrawal symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance:",
"     <b>",
"      Note:",
"     </b>",
"     Patients should be switched to the buprenorphine/naloxone combination product for maintenance and for unsupervised therapy; initial target dose: 12-16 mg/day; then adjust dose in 2-4 mg increments/decrements to a dose that adequately suppresses opioid withdrawal; usual range: 4-24 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F143032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 0.3 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Buprenex&reg;: 0.3 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 0.3 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patch, transdermal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Butrans&reg;: 5 mcg/hr (4s) [total buprenorphine 5 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Butrans&reg;: 10 mcg/hr (4s) [total buprenorphine 10 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Butrans&reg;: 20 mcg/hr (4s) [total buprenorphine 20 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, sublingual: 2 mg, 8 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F143016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes patch",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F143102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-III",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11217368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Prescribing of tablets for opioid dependence is limited to physicians who have met the qualification criteria and have received a DEA number specific to prescribing this product. Tablets will be available through pharmacies and wholesalers which normally provide controlled substances.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F11370707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Butrans&trade;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM219146.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM219146.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Subutex&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM285300.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM285300.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1051383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Sublingual: Place tablet under the tongue until dissolved; do not swallow. If 2 or more tablets are needed per dose, all tablets may be placed under the tongue at once, or 2 tablets may be placed under the tongue at a time; to ensure consistent bioavailability, subsequent doses should always be taken the same way.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Administer via deep I.M. injection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Administer slowly, over at least 2 minutes",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F143108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Injection:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acetaminophen, allopurinol, amifostine, aztreonam, cefepime, cisatracurium, cladribine, docetaxel, etoposide phosphate, filgrastim, gemcitabine, granisetron, linezolid, melphalan, oxaliplatin, pemetrexed, piperacillin/tazobactam, propofol, remifentanil, teniposide, thiotepa, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, doxorubicin liposome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Bupivacaine, chlorpromazine, glycopyrrolate and haloperidol, heparin, midazolam.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1051375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection: Protect from exposure to excessive heat of &gt;40&deg;C (&gt;104&deg;F) or prolonged exposure to light.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Sublingual tablet: Store at room temperature of 25&deg;C (77&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1051382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection: Management of moderate to severe pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Sublingual tablet: Treatment of opioid dependence",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F143110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Buprenex&reg; may be confused with Brevibloc&reg;, Bumex&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F143107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness/vertigo, headache, sedation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Miosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Respiratory depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Amblyopia, anaphylactic shock, apnea, bradycardia, conjunctivitis, coma, cyanosis, depersonalization, depression, diplopia, euphoria, hallucinations, hypersensitivity reactions, hypertension, injection site reaction, psychosis, seizures, slurred speech, tachycardia, urinary retention, Wenckebach block",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Tablet:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, chills, depression, dizziness, fever, headache, insomnia, nervousness, pain, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, diarrhea, dyspepsia, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Abscess formation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Lacrimation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, pharyngitis, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, flu-like syndrome, infection, withdrawal syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylactic shock, angioedema, hepatic encephalopathy, hepatic failure, hepatic necrosis, hepatitis (including cytolytic), hepatorenal syndrome, hypersensitivity reactions, transaminases increased",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Transdermal patch:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, hypertension, peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, depression, dizziness, fatigue, fever, headache, hypoesthesia, insomnia, migraine, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Hyperhydrosis, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal discomfort, anorexia, constipation, diarrhea, dyspepsia, nausea, upper abdominal pain, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Application site erythema, application site irritation, application site pruritus, application site rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, joint swelling, muscle spasms, musculoskeletal pain, myalgia, neck pain, pain in extremity, paresthesia, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchitis, cough, dyspnea, nasopharyngitis, pharyngolaryngeal pain, sinusitis, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: ALT increased, angina, angioedema, application site dermatitis, asthma exacerbation, bradycardia, contact dermatitis, diverticulitis, hallucinations, hyper/hypoventilation, hypersensitivity reactions, hypotension, ileus, loss of consciousness, memory impairment, mental impairment, mental status changes, miosis (dose-related), orthostatic hypotension, psychoses, respiratory depression, respiratory distress, respiratory failure, syncope, tachycardia, urinary incontinence, urinary retention, vasodilatation, visual disturbances, withdrawal syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1051387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to buprenorphine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1051371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with head injury; increased intracranial pressure; CNS depression; coma; toxic psychosis; seizures; acute abdominal conditions; biliary tract disease, pancreatitis; severe renal, respiratory, or hepatic insufficiency; hypothyroidism; Addison's disease; urethral stricture, prostatic hypertrophy; acute alcoholism; delirium tremens, kyphoscoliosis, and in children or debilitated patients. Safety and efficacy of injection in children &lt;2 years of age and of sublingual tablets in children &lt;16 years of age have not been established.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1051370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory depression may occur; use with caution and in reduced doses in patients with pre-existing respiratory depression, decreased respiratory reserve, hypoxia, hypercapnia, significant COPD, or cor pulmonale, and in those receiving medications with CNS or respiratory depressant effects; respiratory depression may not be reversible with naloxone; mechanical ventilation may be required.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     May cause CNS depression; warn patients of possible impairment of alertness or physical coordination; interactions with other CNS drugs may occur; physical and psychological dependence may occur; abrupt discontinuation after prolonged use may result in withdrawal symptoms (",
"     <b>",
"      Note:",
"     </b>",
"     Compared to full opioid agonists, withdrawal from buprenorphine may be milder and may be delayed in onset); narcotic antagonist activity of buprenorphine may precipitate acute narcotic withdrawal in opioid-dependent individuals.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Hepatitis and other hepatic events have been reported in patients receiving buprenorphine for the treatment of opioid dependence; infection with viral hepatitis, concomitant use of potentially hepatotoxic drugs, pre-existing liver enzyme abnormalities, ongoing drug use may have contributed to liver abnormalities. Acute and chronic hypersensitivity reactions have also been reported. Orthostatic hypotension may occur in ambulatory patients.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F143094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2A6 (weak), CYP2C19 (weak), CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F143025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the CNS depressant effect of Buprenorphine. Management: Advise patients receiving buprenorphine about the increased risk of CNS depression if they consume alcohol.  Consider alternatives to buprenorphine for opioid addiction treatment in patients who are dependent on alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Mixed Agonist / Antagonist Opioids may diminish the analgesic effect of Analgesics (Opioid).  Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Buprenorphine. Buprenorphine may decrease the serum concentration of Atazanavir. Management: Avoid this combination in patients un-boosted atazanavir due to possible decreased atazanavir concentrations.  This combination is not contraindicated in patients also receiving ritonavir, but monitoring for buprenorphine toxicity is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Buprenorphine. Boceprevir may increase the serum concentration of Buprenorphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease serum concentrations of the active metabolite(s) of Buprenorphine. Efavirenz may decrease the serum concentration of Buprenorphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Buprenorphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F143027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F143041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects have been observed in animal reproduction studies following buprenorphine subcutaneous and transdermal administration. In humans, withdrawal has been reported in infants of women receiving buprenorphine during pregnancy. Onset of symptoms ranged from day 1 to day 8 of life, most occurring on day 1.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1051378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pain relief, respiratory rate, mental status, blood pressure; liver enzymes (baseline and periodic) with use of sublingual tablets",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1051369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to opiate receptors in the CNS, causing inhibition of ascending pain pathways, altering perception of and response to pain; produces generalized CNS depression. Can be classified as a partial agonist with both agonist and antagonist activity (ie, partial agonist at the mu opioid receptor and an antagonist at the kappa opioid receptor). When used as recommended, buprenorphine acts as a classic mu receptor agonist (like morphine).",
"     <i>",
"      In vitro",
"     </i>",
"     studies demonstrate a very slow rate of dissociation from the mu receptor which may account for buprenorphine's longer duration of action (compared to morphine), unpredictability of reversal by opioid antagonists, and low level of apparent physical dependence.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1051385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: &ge;6 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1051386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes into breast milk at concentrations greater than maternal plasma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Premature neonates 27-32 weeks GA (n=11) (mean &plusmn; SD): 6.2 &plusmn; 2.1 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 4-7 years (n=10) (mean &plusmn; SD): 3.2 &plusmn; 2 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 96%, primarily to alpha and beta globulin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver, via both N-dealkylation (to an active metabolite, norbuprenorphine) and glucuronidation; norbuprenorphine also undergoes glucuronidation; two other unidentified metabolites have been found; extensive first-pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Premature neonates 27-32 weeks GA (n=11) (mean &plusmn; SD): 20 &plusmn; 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 2.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sublingual: Adults: 37 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 30% of the dose is excreted in the urine (1% as unchanged drug; 9.4% as conjugated drug; 2.7% as norbuprenorphine; and 11% as conjugated norbuprenorphine) and 69% in feces (33% as unchanged drug; 5% as conjugated drug; 21% as norbuprenorphine; and 2% as conjugated norbuprenorphine)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Related to hepatic blood flow",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Premature neonates 27-32 weeks GA (n=11): 0.23 &plusmn; 0.07 L/hour/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 4-7 years: 3.6 &plusmn; 1.1 L/hour/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 0.78-1.32 L/hour/kg",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1051377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/30/43494?source=see_link\">",
"      see \"Buprenorphine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause postural hypotension (use caution when changing positions from lying or sitting to standing); avoid alcohol, sedatives, benzodiazepines, tranquilizers, and antidepressants; report the use of other prescription and nonprescription medications to your physician and pharmacist. May be habit-forming; use exactly as directed; do not increase dose or frequency; do not discontinue abruptly, dose should be tapered to prevent withdrawal. May cause dry mouth.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1051388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Equianalgesic doses (parenteral): Buprenorphine 0.3 mg = morphine 10 mg; buprenorphine has a longer duration of action than morphine",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Symptoms of overdose include CNS and respiratory depression, pinpoint pupils, hypotension, and bradycardia; treatment is supportive; naloxone may have limited effects in reversing respiratory depression; doxapram has also been used as a respiratory stimulant.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Neonatal withdrawal symptoms (including tremor, agitation, hypertonia, and myoclonus) have been reported in infants of women receiving buprenorphine sublingual tablets during pregnancy; onset of symptoms ranged from day 1 to day 8 of life, most occurring on day 1 of life; rare cases of convulsions (with one case of apnea and bradycardia) have also been reported",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Barrett DA, Simpson J, Rutter N, et al, &ldquo;The Pharmacokinetics and Physiological Effects of Buprenorphine Infusion in Premature Neonates,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1993, 36(3):215-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26071/abstract-text/ 9114907 /pubmed\" id=\" 9114907 \" target=\"_blank\">",
"        9114907",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hamunen K, Olkkola KT, and Maunuksela EL, &ldquo;Comparison of the Ventilatory Effects of Morphine and Buprenorphine in Children,&rdquo;",
"      <i>",
"       Acta Anaesthesiol Scand",
"      </i>",
"      , 1993, 37(5):449-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26071/abstract-text/8356856/pubmed\" id=\"8356856\" target=\"_blank\">",
"        8356856",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maunuksela EL, Korpela R, and Olkkola KT, &ldquo;Comparison of Buprenorphine With Morphine in the Treatment of Postoperative Pain in Children,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1988, 67(3):233-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26071/abstract-text/ 3344976 /pubmed\" id=\" 3344976 \" target=\"_blank\">",
"        3344976",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maunuksela EL, Korpela R, and Olkkola KT, &ldquo;Double-Blind, Multiple-Dose Comparison of Buprenorphine and Morphine in Postoperative Pain of Children,&rdquo;",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 1988, 60(1):48-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26071/abstract-text/3337794/pubmed\" id=\"3337794\" target=\"_blank\">",
"        3337794",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olkkola KT, Leijala MA, and Maunuksela EL, &ldquo;Paediatric Ventilatory Effects of Morphine and Buprenorphine Revisited,&rdquo;",
"      <i>",
"       Paediatr Anaesth",
"      </i>",
"      , 1995, 5(5):303-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26071/abstract-text/7489472/pubmed\" id=\"7489472\" target=\"_blank\">",
"        7489472",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olkkola KT, Maunuksela EL, and Korpela R, &ldquo;Pharmacokinetics of Intravenous Buprenorphine in Children,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1989, 28(2):202-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26071/abstract-text/2775626/pubmed\" id=\"2775626\" target=\"_blank\">",
"        2775626",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12918 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-543E46505B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_29_26071=[""].join("\n");
var outline_f25_29_26071=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11370705\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143056\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143057\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051379\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051372\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143032\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143016\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143102\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11217368\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11370707\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051383\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143108\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051375\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051382\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143110\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143107\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051387\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051371\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051370\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143094\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143025\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143027\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143041\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051378\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051369\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051385\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051386\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051377\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051388\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12918\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12918|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=related_link\">",
"      Buprenorphine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/30/43494?source=related_link\">",
"      Buprenorphine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_29_26072="Vulvovaginal complaints in the prepubertal child";
var content_f25_29_26072=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vulvovaginal complaints in the prepubertal child",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/29/26072/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/29/26072/contributors\">",
"     Marc R Laufer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/29/26072/contributors\">",
"     S Jean Emans, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/29/26072/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/29/26072/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/29/26072/contributors\">",
"     George A Woodward, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/29/26072/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/29/26072/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/29/26072/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vulvovaginal complaints in prepubertal children may be the result of infection, congenital abnormalities, trauma, or dermatologic conditions. Vaginitis may have a nonspecific etiology or may be due to known pathogens. It is the commonest gynecological problem in prepubertal girls [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26072/abstract/1\">",
"     1",
"    </a>",
"    ]. Symptoms include vaginal discharge, erythema, soreness, pruritus, dysuria, and bleeding. Occasionally, urinary tract or bowel symptoms may be interpreted by a child as vulvar or vaginal complaints.",
"   </p>",
"   <p>",
"    This topic will discuss common vulvovaginal disorders in this population. The gynecological history and physical examination and techniques for obtaining cultures in these children are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43316?source=see_link\">",
"     \"Gynecologic examination of the newborn and child\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NONSPECIFIC VULVOVAGINITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonspecific vulvovaginitis is responsible for 25 to 75 percent of vulvovaginitis in prepubertal girls [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26072/abstract/2\">",
"     2",
"    </a>",
"    ]. There are a number of potential factors in children that increase their risk of vulvovaginitis: lack of labial development, unestrogenized thin mucosa, more alkaline pH (pH 7) than postmenarchal",
"    <span class=\"nowrap\">",
"     girls/women,",
"    </span>",
"    poor hygiene, bubble baths, shampoos, deodorant soaps, obesity, foreign bodies, and choice of clothing (leotards, tights, and blue jeans).",
"   </p>",
"   <p>",
"    Chronic masturbatory activity can lead to vulvar irritation with occasional thickening of the clitoral hood. Sexual abuse is another etiology of nonspecific vulvovaginitis. Some girls with nonspecific vulvovaginitis seem to experience recurrences at the time of upper respiratory infections.",
"   </p>",
"   <p>",
"    Once a specific etiology (listed below) for the symptoms has been excluded, the following recommendation for parents may be of help:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoid sleeper pajamas. Nightgowns allow air to circulate.",
"     </li>",
"     <li>",
"      Cotton underpants. Double-rinse underwear after washing to avoid residual irritants. Do not use fabric softeners for underwear and swimsuits.",
"     </li>",
"     <li>",
"      Avoid tights, leotards, and leggings. Skirts and loose-fitting pants allow air to circulate.",
"     </li>",
"     <li>",
"      Daily warm bathing is helpful as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Allow the child to soak in clean water (no soap) for 10 to 15 minutes. Adding vinegar or baking soda to the water has not been specifically studied but from our experience is not more efficacious than clean water alone.",
"     </li>",
"     <li>",
"      Use soap to wash regions other than the genital area just before taking the child out of the tub. Limit use of any soap on genital areas.",
"     </li>",
"     <li>",
"      Rinse the genital area well and gently pat dry.",
"     </li>",
"     <li>",
"      A hair dryer on the cool setting may be helpful to assist with drying the genital region.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Do not use bubble baths or perfumed soaps.",
"     </li>",
"     <li>",
"      If the vulvar area is tender or swollen, cool compresses may relieve the discomfort. Wet wipes can be used instead of toilet paper for wiping. Emollients may help protect skin.",
"     </li>",
"     <li>",
"      Review hygiene with the child. Emphasize wiping front-to-back after bowel movements. If she has trouble remembering, try having her sit backwards on the toilet (facing the toilet). Children younger than five should be supervised or assisted in toilet hygiene.",
"     </li>",
"     <li>",
"      Avoid letting children sit in wet swimsuits for long periods of time after swimming.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These techniques usually result in resolution of nonspecific mucoid discharge",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    odor within two to three weeks. If symptoms persist or recur, the possibility of a foreign body or specific infection should be considered. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Foreign body'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H3\">",
"     'Specific infections'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although not indicated for most nonspecific vaginal discharge, which resolves with the measures above, antibiotic therapy may hasten the resolution of a purulent vaginal discharge (despite a negative culture for specific infections, such as group A streptococcus) that does not respond to hygiene measures and for which other diagnoses have been excluded. Alternative regimens include: a 10-day course of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"     amoxicillin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/26/34214?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    ; topical",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21425?source=see_link\">",
"     metronidazole",
"    </a>",
"    ; or topical",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Occasionally, a short course of estrogen-containing cream (eg, Premarin) can thicken the vaginal mucosa and make it more resistant to recurrent nonspecific infections. Again, making sure to exclude the conditions described below is important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SPECIFIC INFECTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pinworm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pinworms can cause vulvar symptoms, such as itching. Children with recurrent episodes of vulvar",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    perianal itching, especially at night, should be examined for pinworms and treated empirically, if indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2583?source=see_link\">",
"     \"Enterobiasis and trichuriasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Respiratory and enteric flora",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children may pass respiratory flora from the nose and oral pharynx to the vulvar area. Respiratory pathogens include: Streptococcus pyogenes (group A streptococcus), S. aureus, H. influenzae, S. pneumoniae, N. meningitidis, and B. catarrhalis. Likewise, enteric pathogens, such as Shigella and Yersinia, may cause vaginitis. Streptococcus pyogenes is the most commonly identified pathogen in prepubertal girls. Depending upon the definition of vulvovaginitis (vulvitis versus vaginitis only), the prior use of antibiotics, the type of culture obtained (vaginal versus introital), and the clinic setting, typically about 20 percent of girls with vulvovaginitis have S. pyogenes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26072/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Vaginal cultures for respiratory and enteric flora should be obtained if vulvovaginitis persists or is purulent. Antimicrobial therapy for vulvovaginitis caused by respiratory or enteric bacteria depends upon the organism. Group A streptococcus is treated with penicillin or a similar antibiotic. S. aureus and H. influenzae may resolve with hygiene measures but should be treated if vulvovaginitis is persistent or purulent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Candida",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonization with Candida occurs in 3 to 4 percent of prepubertal girls. Candidal infection is most common in children who have had recent antibiotic therapy, are immunosuppressed, or who wear diapers. It is uncommon in normal prepubertal girls, in whom it is frequently overdiagnosed and wrongly assumed to be the etiology for patients' symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/33/37401?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of diaper dermatitis in infants and children\", section on 'Candidal dermatitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/33/37401?source=see_link&amp;anchor=H27#H27\">",
"     \"Overview of diaper dermatitis in infants and children\", section on 'Antifungal agents'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15386?source=see_link\">",
"     \"Candida vulvovaginitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Gardnerella vaginalis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gardnerella vaginalis is generally not associated with a vaginal discharge in prepubertal girls. A possible relationship with sexual abuse has been disputed. In one study, Gardnerella was identified in 14.6 percent of sexually abused girls compared to only 4.2 percent of control girls [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26072/abstract/8\">",
"     8",
"    </a>",
"    ]. In another report, however, the incidence of Gardnerella was equivalent in sexually abused girls and the female children of friends of the author (controls) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26072/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Sexually transmitted diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexually transmitted diseases in children typically result from sexual abuse. Pathogens include",
"    <em>",
"     Neisseria gonorrhoeae",
"    </em>",
"    ,",
"    <em>",
"     Chlamydia trachomatis",
"    </em>",
"    , human papillomavirus,",
"    <em>",
"     Treponema pallidum",
"    </em>",
"    , and herpes simplex virus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=see_link&amp;anchor=H16#H16\">",
"     \"Evaluation of sexual abuse in children and adolescents\", section on 'STI testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Neisseria gonorrhoeae",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Neisseria gonorrhoeae",
"    </em>",
"    usually presents with a green or mucoid vaginal discharge; the infection is rarely asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26072/abstract/10\">",
"     10",
"    </a>",
"    ] but occasionally may be found without symptoms in girls being evaluated for sexual abuse. The diagnosis is made by culturing girls with an evident discharge. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43316?source=see_link&amp;anchor=H4#H4\">",
"     \"Gynecologic examination of the newborn and child\", section on 'How to obtain cultures from children'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/35/26166?source=see_link\">",
"     \"Diagnosis of gonococcal infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=see_link&amp;anchor=H17#H17\">",
"     \"Evaluation of sexual abuse in children and adolescents\", section on 'Prepubertal victims'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Chlamydia trachomatis",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Chlamydia trachomatis",
"    </em>",
"    is primarily transmitted to newborns via exposure to an infected mother's genital flora during vaginal birth.",
"    <em>",
"     C. trachomatis",
"    </em>",
"    is also associated with vaginitis and sexual abuse, although patients may be asymptomatic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27992?source=see_link&amp;anchor=H2#H2\">",
"     \"Chlamydia trachomatis infections in the newborn\", section on 'Epidemiology and transmission'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=see_link&amp;anchor=H17#H17\">",
"     \"Evaluation of sexual abuse in children and adolescents\", section on 'Prepubertal victims'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Trichomonas vaginalis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trichomonas vaginalis can occur in newborns, but is rare in the prepubertal child. Thus, except for infants, sexual contact is likely if trichomonal organisms are identified (by an experienced technician or clinician) in vaginal secretions by wet mount examination or culture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=see_link&amp;anchor=H27#H27\">",
"     \"Evaluation of sexual abuse in children and adolescents\", section on 'STIs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Condylomata acuminata",
"    </span>",
"    &nbsp;&mdash;&nbsp;Condylomata acuminata are skin-colored or pink lesions that may be warty or smooth flattened papules. They are caused by the human papillomavirus (HPV). In children younger than two to three years of age, these lesions are likely the result of maternal-child transmission during vaginal birth, but may be acquired by sexual or nonsexual transmission. It is not necessary for the mother to be symptomatic or to have a history of HPV for this transmission to occur. HPV testing of mothers does not exclude sexual abuse and therefore is not generally performed; if sexual abuse is of concern, evaluation is needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=see_link&amp;anchor=H27#H27\">",
"     \"Evaluation of sexual abuse in children and adolescents\", section on 'STIs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In older children, sexual transmission and evaluation for potential sexual abuse should be considered and if there is a concern, children should be interviewed and evaluated by appropriately experienced professionals. Auto- and hetero-inoculation and indirect transmission via fomites are other possibilities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=see_link&amp;anchor=H27#H27\">",
"     \"Evaluation of sexual abuse in children and adolescents\", section on 'STIs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis is usually made clinically without a biopsy. A biopsy can, however, confirm the presence of HPV and leads to a conclusive diagnosis. HPV DNA typing may help the health care provider formulate a follow-up surveillance plan (",
"    <a class=\"graphic graphic_table graphicRef76394 \" href=\"UTD.htm?0/27/443\">",
"     table 1",
"    </a>",
"    ). There are over 100 distinct HPV subtypes; approximately 40 types are specific for the anogenital epithelium and have varying potentials to cause malignant change, such as cervical or anal cancer (",
"    <a class=\"graphic graphic_table graphicRef76394 \" href=\"UTD.htm?0/27/443\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26455?source=see_link\">",
"     \"Virology of human papillomavirus infections and the link to cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=see_link\">",
"     \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Spontaneous resolution occurs within five years in more than 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26072/abstract/11\">",
"     11",
"    </a>",
"    ]. Expectant management is a potential initial approach to asymptomatic pediatric condylomata; however, many families choose to have them treated. Treatment options have not been well studied and have included laser therapy (which requires anesthesia), trichloroacetic acetic (which is not well tolerated in this age group), and topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    cream (which needs careful monitoring to assure vulvar reactions are not severe). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8312?source=see_link\">",
"     \"Condylomata acuminata (anogenital warts) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     FOREIGN BODY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Foreign bodies in children can cause acute and chronic recurrent vulvovaginitis. Chronic vaginal discharge, intermittent bleeding or spotting,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a foul smelling odor are the usual clinical manifestations. Toilet paper is the most common foreign body found in the vaginas of children; small toys, hair bands, and paper clips are also common.",
"   </p>",
"   <p>",
"    The foreign body can often be removed by a calgi swab (for toilet paper) or with irrigation with warmed fluid, after the introitus has been treated with a topical anesthetic agent, such as a small amount of Xylocaine jelly or EMLA (although it is not FDA approved for utilization on mucus membranes). Examination under sedation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anesthesia may be necessary for extraction of larger foreign bodies and those that cannot be removed with irrigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     POLYPS OR TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A vaginal polyp or tumor may also present with chronic discharge. Sarcoma botryoides can involve the hymen, lower urethra, or anterior vaginal wall. The peak incidence is at age two to five years. The tumor is more likely to arise higher up along the anterior vaginal wall towards the cervix in older preadolescent girls. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16377?source=see_link\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31208?source=see_link&amp;anchor=H8#H8\">",
"     \"Vaginal cancer\", section on 'Sarcoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Benign polyps can also occur involving the vagina and hymenal area but are rare.",
"   </p>",
"   <p>",
"    Treatment is surgical; the specific procedure depends upon the pathology. A simple polyp can be removed with surgical excision. A vaginal sarcoma requires biopsy for diagnosis and then chemotherapy and conservative surgery with the aim to treat the tumor while maintaining future sexual and reproductive function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31208?source=see_link&amp;anchor=H12#H12\">",
"     \"Vaginal cancer\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SYSTEMIC ILLNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measles, chickenpox, scarlet fever, Epstein-Barr virus (EBV, infectious mononucleosis) Stevens-Johnson syndrome, Crohn's disease, and Kawasaki disease have all been associated with vulvovaginal signs and symptoms, such as vesicles, discharge, fistulae, ulcers, and inflammation. Severe cases of Stevens-Johnson syndrome or graft-versus-host disease after bone marrow transplant may result in vaginal stenosis or obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26072/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Persistent complaints of vaginal bleeding or discharge that are otherwise unexplained may be a manifestation of a serious underlying medical problem (eg, rhabdomyosarcoma or other tumor) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26072/abstract/13\">",
"     13",
"    </a>",
"    ]. Pelvic examination under anesthesia, vaginoscopy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cystoscopy may be necessary if genital examination and noninvasive imaging fail to provide an explanation for such complaints.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     VULVAR ULCERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsexually transmitted vulvar ulcers, sometimes called Lipschutz ulcers, \"virginal ulcers\", or \"aphthous ulcers\", are typically seen in girls age 10 to 15 years (",
"    <a class=\"graphic graphic_picture graphicRef68284 \" href=\"UTD.htm?31/62/32739\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26072/abstract/14\">",
"     14",
"    </a>",
"    ]. Clinical features may include one or more acutely painful ulcers (often &gt;1 cm) with a purulent base and raised edges and often systemic symptoms (eg, fatigue, malaise, fever, headache).",
"   </p>",
"   <p>",
"    The etiology often cannot be determined, although viral infections such as influenza A, EBV, and CMV have been associated with these painful lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26072/abstract/14-19\">",
"     14-19",
"    </a>",
"    ]. A careful sexual history should be taken and testing for STDs, such as herpes simplex, performed even though in most cases the ulcers occur before the onset of genital or oral sexual activity. A CBC, differential, and monospot test, as well as acute and convalescent serum, can be obtained to look for EBV.",
"   </p>",
"   <p>",
"    Although most girls can be treated at home, at times patients require admission for foley catheter drainage due to the inability to urinate, antibiotics (if the ulcers are superinfected), topical anesthetics, and pain management. Oral corticosteroids have also been prescribed for these ulcers, but controlled studies are lacking. These ulcers often heal completely in one to three weeks, but may recur. Persistent ulcers can occur in girls with Crohn's disease. Recurrent vulvar ulcers, especially if associated with evidence of systemic involvement and vasculitis (oral lesions, uveitis, arthritis) should suggest the possibility of Behcet's disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     URINARY TRACT PATHOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Ectopic ureter",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ectopic ureter can cause chronic vulvar irritation and wetness in girls. The ectopic ureter arises from the upper pole of a duplex collecting system, or from a dysplastic kidney. An ultrasound evaluation may suggest this diagnosis, but an intravenous pyelogram is a more sensitive test. Treatment is surgical. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39989?source=see_link\">",
"     \"Ectopic ureter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Urethral prolapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;In prepubertal girls, the distal end of the urethra can prolapse either partially or in a complete circumferential fashion. The tissue may be friable and become infected, but rarely becomes necrotic. Children with urethral prolapse present with bleeding, dysuria,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    difficulty with urination.",
"   </p>",
"   <p>",
"    We suggest that prepubertal girls with symptomatic urethral prolapse be treated with topical estrogen therapy. The distal urethra is estrogen-sensitive and may respond to treatment with estrogen, as in postmenopausal women with this problem. Sitz baths twice daily may also be helpful. Topical estrogen cream is applied twice daily after the sitz bath for two weeks, then the urethra is reassessed and treatment is continued if the prolapse has not resolved and is still present. The prolapse will usually resolve within a few weeks of topical estrogen treatment but can sometimes take longer. If the distal urethra is necrotic, it may require surgery. If there is persistence of the prolapse, assessment for a urethral polyp may be indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10295?source=see_link&amp;anchor=H7#H7\">",
"     \"The pediatric physical examination: The perineum\", section on 'Females'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     CUTANEOUS VULVAR DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prepubertal hypoestrogenic tissues are atrophic and more susceptible to infection and irritation. The majority of vulvar symptoms in children are due to local irritants, foreign bodies, or infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26072/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Lichen sclerosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lichen sclerosus is a dermatologic abnormality of unclear etiology. Clinical manifestation in girls include itching, discomfort in the vulvar area, bowel or bladder symptoms, discharge, or bleeding. The vulvar tissue displays a white onion skin-like lesion, typically in an hourglass configuration with the whitened skin circumscribing the vulvar and perianal areas (",
"    <a class=\"graphic graphic_picture graphicRef57910 \" href=\"UTD.htm?39/18/40224\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef55275 \" href=\"UTD.htm?6/33/6687\">",
"     picture 3",
"    </a>",
"    ). There may also be punctate hemorrhages, which can occur anywhere on the affected skin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6874?source=see_link\">",
"     \"Vulvar lichen sclerosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis in children is made by visual inspection; a biopsy is rarely required, in contrast to the adult population. Lichen sclerosus can be associated with underlying malignancies in adults, but this does not appear to be true for children.",
"   </p>",
"   <p>",
"    Treatment consists of topical, high-potency corticosteroids (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/59/17333?source=see_link\">",
"     clobetasol",
"    </a>",
"    0.05 percent ointment or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/37/43603?source=see_link\">",
"     halobetasol",
"    </a>",
"    0.05 percent ointment), applied twice daily for two weeks. The vulva is then reassessed to determine response and further treatment. High-potency steroids are usually needed for 6 to 12 weeks, but may need to continue longer. It may take weeks to months of treatment for the condition to resolve. Once the symptoms and visible signs have resolved, the topical steroid is tapered; if the steroids are discontinued abruptly, there can be a \"rebound\" effect. An additional course of steroids may be necessary if the disease recurs.",
"   </p>",
"   <p>",
"    Untreated, lichen sclerosus can result in long-term sexual dysfunction due to loss of the normal labia and the normal architecture of the vulva. Scarring of the clitoral hood may occur with entrapment of the underlying glands, resulting in pain upon sexual excitation and engorgement of the clitoris. This may necessitate a surgical procedure to try to correct the abnormality, but repetitive scarring of the clitoral hood may occur. If there is clitoral hood scarring, then a \"clitoral entrapment syndrome\" can occur. We have described a technique of clitoroplasty with reconfiguration of the clitoral hood and placement of Surgicel in order to try to avoid rescarring of the area [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26072/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An excellent information handout for parents is available through the North American Society for Pediatric and Adolescent Gynecology website:",
"    <a class=\"external\" href=\"file://www.naspag.org/index.php/pagepediatricvulvar\">",
"     file://www.naspag.org/index.php/pagepediatricvulvar",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Hemangiomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemangiomas occur on the vulva, as on other body surfaces. Most hemangiomas will involute between two and five years of age and require no further intervention. Once involuted, the remaining skin and fatty tissue can be evaluated to determine whether the lesion is of significant size to necessitate a surgical resection.",
"   </p>",
"   <p>",
"    Hemangiomas of the vulvar and clitoral region rarely bleed. A complete evaluation, including vascular magnetic resonance imaging, can be helpful for determining the extent of internal involvement of a larger hemangioma. Co-management with a vascular surgeon is recommended for hemangiomas that require surgical intervention.",
"   </p>",
"   <p>",
"    The clinical features, evaluation, and management of hemangiomas are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44665?source=see_link\">",
"     \"Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5495?source=see_link\">",
"     \"Evaluation and diagnosis of infantile hemangiomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25546?source=see_link\">",
"     \"Management of infantile hemangiomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Labial adhesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology and frequency of labial adhesions (also called labial agglutination and synechia vulvae) are unknown. They can be partial, involving only the upper or lower labia, or complete. A small pinhole orifice may be present that functions as a means for urine to exit from behind the fused labia.",
"   </p>",
"   <p>",
"    Labial adhesions may be asymptomatic or cause a pulling sensation, difficulty with urination, recurrent urinary tract infections, or recurrent vaginal infections. No treatment is necessary if the adhesions are asymptomatic, involve only a small portion of the labia, and are not affecting the urine stream. The adhesions may resolve when estrogen production increases at puberty.",
"   </p>",
"   <p>",
"    Labial adhesions should be treated if they affect urination by diverting a normal stream of urine. Treatment consists of topical estrogen cream (eg, Premarin cream) applied twice daily at the point of midline fusion where there is a thin white line [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26072/abstract/21\">",
"     21",
"    </a>",
"    ]. With the application of the estrogen cream, great care should be taken so as not to traumatically tear the adhesion.",
"   </p>",
"   <p>",
"    Therapy is continued until the labial adhesions resolve. Breast bud formation is a possible side effect, which will resolve after the cessation of the topical estrogen cream. This complication is less likely if the cream is applied sparingly and directly to the adhesion.",
"   </p>",
"   <p>",
"    The response of labial adhesions to topical estrogen therapy was illustrated in a retrospective review of 109 girls (three months to 10 years of age) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26072/abstract/22\">",
"     22",
"    </a>",
"    ]. Topical estrogen therapy was successful in 79 percent of patients after a mean duration of four months. Minimal breast development occurred in six girls (5 percent), and vaginal bleeding in one (&lt;1 percent). In our experience, labial adhesions resolve in nearly all girls treated with correct technique for two to six weeks. Successful separation should be followed by attention to hygiene, daily baths, and the application of a bland ointment, such as A&amp;D Ointment or white petroleum jelly, for 6 to 12 months",
"   </p>",
"   <p>",
"    Failure of medical therapy tends to occur with thick adhesions (3 to 4 mm in width) with no thin translucent raphe [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26072/abstract/23\">",
"     23",
"    </a>",
"    ]. The most common reason for medical failure is placement of the cream in the wrong location or placement of too small an amount of cream.",
"   </p>",
"   <p>",
"    Surgical intervention for labial adhesions is reserved for rare patients with complete obstruction of urine flow in whom estrogen cream cannot be applied for psychosocial reasons or has been unsuccessful after an adequate trial (as described above). With these indications, the authors have performed only one surgical separation in the past 10 years. When necessary, surgical separation is performed with sedation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anesthesia and followed by topical estrogen cream for one to two weeks and then application of a bland emollient (eg, white petroleum jelly) for 6 to 12 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vulvar trauma can cause significant bleeding because the area is highly vascular and children do not have mature labia with fat pads, which protect the vulvar area of adults. Girls who sustain straddle or inline skating injuries may require surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26072/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35669?source=see_link\">",
"     \"Straddle injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A careful history should be obtained and physical examination performed. The history must correlate with the physical findings to confirm nonsexual trauma. If a child has a straddle injury, she will most likely have an injury to the anterior area of the vulva, including the mons, clitoral hood, and anterior aspect of the labia (",
"    <a class=\"graphic graphic_picture graphicRef70056 graphicRef78842 graphicRef60772 graphicRef68436 graphicRef79041 \" href=\"UTD.htm?37/56/38794\">",
"     picture 4A-E",
"    </a>",
"    ). An injury to the posterior fourchette and hymenal area suggest possible sexual abuse. As an example, a laceration to the lower half of the hymenal area (using a clock, the location would be three o'clock to nine o'clock) is consistent with a penetrating injury and must be further explored (",
"    <a class=\"graphic graphic_picture graphicRef50009 graphicRef62823 \" href=\"UTD.htm?8/36/8776\">",
"     picture 5A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26072/abstract/25\">",
"     25",
"    </a>",
"    ]. Normal hymenal variants must be understood to be able to identify abnormal hymenal findings due to trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26072/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43316?source=see_link&amp;anchor=H10#H10\">",
"     \"Gynecologic examination of the newborn and child\", section on 'Evaluation of the hymen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Assessment of ability to urinate is essential as a large, obstructive hematoma can result from blunt trauma to the vulva. Ice to the area, bladder drainage, and pain medications are appropriate support measures for a girl with a large hematoma. Most vulvar hematomas will resolve spontaneously. Surgical drainage is not usually needed because the hematoma is usually the result of a compromise to small vessels that are difficult to identify if the hematoma is opened. In addition, surgical disruption of the skin facilitates introduction of bacteria and an abscess can result. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44071?source=see_link\">",
"     \"Evaluation and management of lower genital tract trauma in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less common vulvar lesions in this age group include neurofibromas, leiomyomas or leiomyosarcomas, granular cell tumors, and nodular fasciitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26072/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/12/14530?source=see_link\">",
"       \"Patient information: Lichen sclerosus (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vulvovaginal complaints in prepubertal children may be the result of infection, congenital abnormalities, trauma, or dermatologic conditions. Vaginitis may have a nonspecific etiology; may be due to known pathogens, such as pinworm, candida, or respiratory or oral flora; or may be related to a foreign body.",
"     </li>",
"     <li>",
"      Sexually transmitted diseases in prepubertal children typically result from sexual abuse.",
"     </li>",
"     <li>",
"      A vaginal polyp or tumor may also present with chronic discharge and some systemic illnesses also affect the vagina.",
"     </li>",
"     <li>",
"      Prepubertal hypoestrogenic tissues are atrophic and thus more susceptible to local irritants, foreign bodies, and infection.",
"     </li>",
"     <li>",
"      The most common respiratory pathogen causing vaginitis is Streptococcus pyogenes (group A streptococcus); this infection should be promptly treated with penicillin or similar antibiotic. Mucoid discharge associated with organisms such as S. aureus or H. influenzae may resolve with hygiene, and thus antibiotics are usually prescribed for persistent symptoms or purulent discharge. Culture-negative but persistent vaginitis may resolve with treatments, such as a 10 day course of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"       amoxicillin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/26/34214?source=see_link\">",
"       amoxicillin-clavulanate",
"      </a>",
"      , topical",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21425?source=see_link\">",
"       metronidazole",
"      </a>",
"      , or topical",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"       clindamycin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Specific infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest removing small foreign bodies with a swab or with irrigation with warmed fluid, after the introitus has been treated with a small amount of topical anesthetic agent, in some children with larger foreign bodies or those that are not removed by irrigation, conscious sedation or examination under anesthesia may be necessary (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Foreign body'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tumors and polyps are surgically removed. The scope of the procedure depends upon the specific pathology. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Polyps or tumors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that children with urethral prolapse receive topical estrogen cream applied twice daily for two weeks (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Sitz baths may also be helpful during estrogen treatment. The patient should then be reassessed to see if the urethral prolapse has resolved. In some patients with necrotic tissue, surgical intervention may be required. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Urethral prolapse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lichen sclerosus should be treated to prevent progression. We suggest administration of topical corticosteroids (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Lichen sclerosus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest treatment of labial adhesions with topical estrogen cream and gentle traction with care taken so as not to traumatically tear the adhesion (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Labial adhesions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26072/abstract/1\">",
"      Joishy M, Ashtekar CS, Jain A, Gonsalves R. Do we need to treat vulvovaginitis in prepubertal girls? BMJ 2005; 330:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26072/abstract/2\">",
"      Garden AS. Vulvovaginitis and other common childhood gynaecological conditions. Arch Dis Child Educ Pract Ed 2011; 96:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26072/abstract/3\">",
"      Stricker T, Navratil F, Sennhauser FH. Vulvovaginitis in prepubertal girls. Arch Dis Child 2003; 88:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26072/abstract/4\">",
"      Ranelovi G, Mladenovi V, Risti L, et al. Microbiological aspects of vulvovaginitis in prepubertal girls. Eur J Pediatr 2012; 171:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26072/abstract/5\">",
"      Yilmaz AE, Celik N, Soylu G, et al. Comparison of clinical and microbiological features of vulvovaginitis in prepubertal and pubertal girls. J Formos Med Assoc 2012; 111:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26072/abstract/6\">",
"      Sikani-Dugi N, Pustisek N, Hirsl-Heej V, Luki-Grli A. Microbiological findings in prepubertal girls with vulvovaginitis. Acta Dermatovenerol Croat 2009; 17:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26072/abstract/7\">",
"      Cuadros J, Maz&oacute;n A, Martinez R, et al. The aetiology of paediatric inflammatory vulvovaginitis. Eur J Pediatr 2004; 163:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26072/abstract/8\">",
"      Bartley DL, Morgan L, Rimsza ME. Gardnerella vaginalis in prepubertal girls. Am J Dis Child 1987; 141:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26072/abstract/9\">",
"      Ingram DL, White ST, Lyna PR, et al. Gardnerella vaginalis infection and sexual contact in female children. Child Abuse Negl 1992; 16:847.",
"     </a>",
"    </li>",
"    <li>",
"     Emans SJ, Laufer MR. Pediatric and Adolescent Gynecology, 6th, Lippincott Williams &amp; Wilkins, Philadelphia 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26072/abstract/11\">",
"      Allen AL, Siegfried EC. The natural history of condyloma in children. J Am Acad Dermatol 1998; 39:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26072/abstract/12\">",
"      Spiryda LB, Laufer MR, Soiffer RJ, Antin JA. Graft-versus-host disease of the vulva and/or vagina: diagnosis and treatment. Biol Blood Marrow Transplant 2003; 9:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26072/abstract/13\">",
"      Striegel AM, Myers JB, Sorensen MD, et al. Vaginal discharge and bleeding in girls younger than 6 years. J Urol 2006; 176:2632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26072/abstract/14\">",
"      Farhi D, Wendling J, Molinari E, et al. Non-sexually related acute genital ulcers in 13 pubertal girls: a clinical and microbiological study. Arch Dermatol 2009; 145:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26072/abstract/15\">",
"      Lampert A, Assier-Bonnet H, Chevallier B, et al. Lipschutz's genital ulceration: a manifestation of Epstein-Barr virus primary infection. Br J Dermatol 1996; 135:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26072/abstract/16\">",
"      Barnes CJ, Ali&oacute; AB, Cunningham BB, Friedlander SF. Epstein-Barr virus-associated genital ulcers: an under-recognized disorder. Pediatr Dermatol 2007; 24:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26072/abstract/17\">",
"      Huppert JS, Gerber MA, Deitch HR, et al. Vulvar ulcers in young females: a manifestation of aphthosis. J Pediatr Adolesc Gynecol 2006; 19:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26072/abstract/18\">",
"      Wetter DA, Bruce AJ, MacLaughlin KL, Rogers RS 3rd. Ulcus vulvae acutum in a 13-year-old girl after influenza A infection. Skinmed 2008; 7:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26072/abstract/19\">",
"      Piippo S, Lenko H, Vuento R. Vulvar symptoms in paediatric and adolescent patients. Acta Paediatr 2000; 89:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26072/abstract/20\">",
"      Breech LL, Laufer MR. Surgicel in the management of labial and clitoral hood adhesions in adolescents with lichen sclerosus. J Pediatr Adolesc Gynecol 2000; 13:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26072/abstract/21\">",
"      Tebruegge M, Misra I, Nerminathan V. Is the topical application of oestrogen cream an effective intervention in girls suffering from labial adhesions? Arch Dis Child 2007; 92:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26072/abstract/22\">",
"      Schober J, Dulabon L, Martin-Alguacil N, et al. Significance of topical estrogens to labial fusion and vaginal introital integrity. J Pediatr Adolesc Gynecol 2006; 19:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26072/abstract/23\">",
"      Bacon JL. Prepubertal labial adhesions: evaluation of a referral population. Am J Obstet Gynecol 2002; 187:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26072/abstract/24\">",
"      Herrmann B, Crawford J. Genital injuries in prepubertal girls from inline skating accidents. Pediatrics 2002; 110:e16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26072/abstract/25\">",
"      Emans SJ, Woods ER, Flagg NT, Freeman A. Genital findings in sexually abused, symptomatic and asymptomatic, girls. Pediatrics 1987; 79:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26072/abstract/26\">",
"      Berenson A, Heger A, Andrews S. Appearance of the hymen in newborns. Pediatrics 1991; 87:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26072/abstract/27\">",
"      Berenson AB, Heger AH, Hayes JM, et al. Appearance of the hymen in prepubertal girls. Pediatrics 1992; 89:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26072/abstract/28\">",
"      McCann J, Voris J, Simon M, Wells R. Perianal findings in prepubertal children selected for nonabuse: a descriptive study. Child Abuse Negl 1989; 13:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26072/abstract/29\">",
"      Fivozinsky KB, Laufer MR. Vulvar disorders in prepubertal girls. A literature review. J Reprod Med 1998; 43:763.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6450 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-555B9DE994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_29_26072=[""].join("\n");
var outline_f25_29_26072=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NONSPECIFIC VULVOVAGINITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SPECIFIC INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pinworm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Respiratory and enteric flora",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Candida",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Gardnerella vaginalis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Sexually transmitted diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Neisseria gonorrhoeae",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Chlamydia trachomatis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Trichomonas vaginalis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Condylomata acuminata",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      FOREIGN BODY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      POLYPS OR TUMORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SYSTEMIC ILLNESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      VULVAR ULCERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      URINARY TRACT PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Ectopic ureter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Urethral prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      CUTANEOUS VULVAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Lichen sclerosus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Labial adhesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6450\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6450|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/62/32739\" title=\"picture 1\">",
"      Vulvar ulcers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/18/40224\" title=\"picture 2\">",
"      Lichen sclerosus in a 10 year old prepubertal girl",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/33/6687\" title=\"picture 3\">",
"      Lichen sclerosus child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/35/39474\" title=\"picture 4A\">",
"      Straddle injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/17/13587\" title=\"picture 4B\">",
"      Straddle injury2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/44/32449\" title=\"picture 4C\">",
"      Straddle injury3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/8/19585\" title=\"picture 4D\">",
"      Straddle injury4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/0/19457\" title=\"picture 4E\">",
"      Straddle injury6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/56/14210\" title=\"picture 5A\">",
"      Rape",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/43/32435\" title=\"picture 5B\">",
"      Rape2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6450|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/27/443\" title=\"table 1\">",
"      Risk of cervical CA with HPV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15386?source=related_link\">",
"      Candida vulvovaginitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=related_link\">",
"      Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27992?source=related_link\">",
"      Chlamydia trachomatis infections in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8312?source=related_link\">",
"      Condylomata acuminata (anogenital warts) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/35/26166?source=related_link\">",
"      Diagnosis of gonococcal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39989?source=related_link\">",
"      Ectopic ureter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2583?source=related_link\">",
"      Enterobiasis and trichuriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44665?source=related_link\">",
"      Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5495?source=related_link\">",
"      Evaluation and diagnosis of infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44071?source=related_link\">",
"      Evaluation and management of lower genital tract trauma in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=related_link\">",
"      Evaluation of sexual abuse in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43316?source=related_link\">",
"      Gynecologic examination of the newborn and child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25546?source=related_link\">",
"      Management of infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/33/37401?source=related_link\">",
"      Overview of diaper dermatitis in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/12/14530?source=related_link\">",
"      Patient information: Lichen sclerosus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16377?source=related_link\">",
"      Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35669?source=related_link\">",
"      Straddle injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10295?source=related_link\">",
"      The pediatric physical examination: The perineum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31208?source=related_link\">",
"      Vaginal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26455?source=related_link\">",
"      Virology of human papillomavirus infections and the link to cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6874?source=related_link\">",
"      Vulvar lichen sclerosus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_29_26073="Bupropion: Drug information";
var content_f25_29_26073=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bupropion: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/7/17526?source=see_link\">",
"    see \"Bupropion: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/11/39096?source=see_link\">",
"    see \"Bupropion: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F143210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aplenzin&trade;;",
"     </li>",
"     <li>",
"      Budeprion SR&reg;;",
"     </li>",
"     <li>",
"      Budeprion XL&reg; [DSC];",
"     </li>",
"     <li>",
"      Buproban&reg;;",
"     </li>",
"     <li>",
"      Forfivo&trade; XL;",
"     </li>",
"     <li>",
"      Wellbutrin SR&reg;;",
"     </li>",
"     <li>",
"      Wellbutrin XL&reg;;",
"     </li>",
"     <li>",
"      Wellbutrin&reg;;",
"     </li>",
"     <li>",
"      Zyban&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F143211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ava-Bupropion SR;",
"     </li>",
"     <li>",
"      Bupropion SR&reg;;",
"     </li>",
"     <li>",
"      Novo-Bupropion SR;",
"     </li>",
"     <li>",
"      PMS-Bupropion SR;",
"     </li>",
"     <li>",
"      ratio-Bupropion SR;",
"     </li>",
"     <li>",
"      Sandoz-Bupropion SR;",
"     </li>",
"     <li>",
"      Wellbutrin&reg; SR;",
"     </li>",
"     <li>",
"      Wellbutrin&reg; XL;",
"     </li>",
"     <li>",
"      Zyban&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F143242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidepressant, Dopamine-Reuptake Inhibitor;",
"     </li>",
"     <li>",
"      Smoking Cessation Aid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F143215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Depression:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Treatment should be periodically evaluated at appropriate intervals to ensure lowest effective dose is used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Immediate release hydrochloride salt:",
"     </i>",
"     Initial: 100 mg twice daily; after 3 days may increase to the usual dose of 100 mg 3 times daily; if no clinical improvement after several weeks, may increase to a maximum dose of 150 mg 3 times daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Sustained release hydrochloride salt:",
"     </i>",
"     Initial: 150 mg daily in the morning; if tolerated, as early as day 4, may increase to a target dose of 150 mg twice daily; if no clinical improvement after several weeks, may increase to a maximum dose of 200 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Extended release:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hydrochloride salt: Initial: 150 mg once daily in the morning; if tolerated, as early as day 4, may increase to 300 mg once daily; if no clinical improvement after several weeks, may increase to a maximum dose of 450 mg once daily.",
"     <b>",
"      Note:",
"     </b>",
"     Forfivo&trade; XL may only be used after initial dose titration with other bupropion products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hydrochloride salt (Forfivo&trade; XL):",
"     <i>",
"      Switching from Wellbutrin&reg; immediate release, SR&reg;, or XL&reg; to Forfivo&trade; XL:",
"     </i>",
"     Patients receiving 300 mg daily of bupropion hydrochloride for at least 2 weeks and requiring a dose increase or patients already taking 450 mg daily of bupropion hydrochloride may switch to Forfivo&trade; XL 450 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hydrobromide salt (Aplenzin&trade;): Initial: 174 mg once daily in the morning; may increase as early as day 4 of dosing to 348 mg once daily (target dose); maximum dose: 522 mg daily.",
"     <b>",
"      Note:",
"     </b>",
"     In patients receiving 348 mg once daily, taper dose down to 174 mg once daily prior to discontinuing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Switching from hydrochloride salt formulation (eg, Wellbutrin&reg; immediate release, SR&reg;, XL&reg;, or  Forfivo&trade; XL) to hydrobromide salt formulation (Aplenzin&trade;):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Bupropion hydrochloride 150 mg daily is equivalent to bupropion hydrobromide 174 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Bupropion hydrochloride 300 mg daily is equivalent to bupropion hydrobromide 348 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Bupropion hydrochloride 450 mg daily is equivalent to bupropion hydrobromide 522 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Seasonal affective disorder (SAD):",
"     </b>",
"     Initial: 150 mg once daily (Wellbutrin XL&reg;) or 174 mg once daily (Aplenzin&trade;) in the morning; if tolerated, may increase after 1 week to 300 mg once daily (Wellbutrin XL&reg;) or 348 mg once daily (Aplenzin&trade;) in the morning.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Prophylactic treatment should be reserved for those patients with frequent depressive episodes and/or significant impairment. Initiate treatment in the Autumn prior to symptom onset, and discontinue in early Spring with dose tapering to 150 mg once daily for 2 weeks (Wellbutrin XL&reg;) or 174 mg once daily (Aplenzin&trade;), then discontinue. Doses &gt;300 mg daily (Wellbutrin XL&reg;) or &gt;348 mg daily (Aplenzin&trade;) have not been studied in SAD.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Smoking cessation (Zyban&reg;, Buproban&reg;):",
"     </b>",
"     Initial: 150 mg once daily for 3 days; increase to 150 mg twice daily; treatment should continue for 7-12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Therapy should begin at least 1 week before target quit date. Target quit dates are generally in the second week of treatment.  If patient successfully quits smoking after 7-12 weeks, may consider ongoing maintenance therapy based on individual patient risk:benefit. Efficacy of maintenance therapy (300 mg daily) has been demonstrated for up to 6 months. Conversely, if significant progress has not been made by the seventh week of therapy, success is unlikely and treatment discontinuation should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      Dosing conversion between hydrochloride salt immediate (Wellbutrin&reg;), sustained (Wellbutrin SR&reg;), and extended release (Wellbutrin XL&reg;, Forfivo&trade; XL) products:",
"     </i>",
"     Convert using same total daily dose (up to the maximum recommended dose for a given dosage form), but adjust frequency as indicated for sustained (twice daily) or extended (once daily) release products.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F143229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/11/39096?source=see_link\">",
"      see \"Bupropion: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      ADHD (unlabeled use):",
"     </b>",
"     Oral (hydrochloride salt): Children and Adolescents: 1.4-6 mg/kg/day (Barrickman, 1995; Conners, 1996)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F143216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Depression: Oral (hydrochloride salt): Initial: 37.5 mg of immediate release tablets twice daily or 100 mg daily of sustained release tablets; increase by 37.5-100 mg every 3-4 days as tolerated to a maximum dose of 300 mg/day (in divided doses). There is evidence that the elderly respond at 150 mg daily in divided doses, but some may require a higher dose.",
"     <b>",
"      Note:",
"     </b>",
"     Patients with Alzheimer&rsquo;s dementia-related depression may require a lower starting dosage of 37.5 mg once or twice daily (100 mg daily sustained release), increased as needed up to 300 mg daily in divided doses (300 mg daily for sustained release) (Rabins, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Smoking cessation: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F143217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Use with caution and consider a reduction in dosing frequency; limited pharmacokinetic information suggests elimination of bupropion and/or the active metabolites may be reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Moderate-to-severe renal impairment: Bupropion exposure was approximately twofold higher compared to normal subjects following a 150 mg single dose administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     End-stage renal failure: Per the manufacturer, the elimination of hydroxybupropion and threohydrobupropion are reduced in patients with end-stage renal failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Forfivo&trade; XL: Use is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F143218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate hepatic impairment: Use with caution; consider a reduced dose and/or frequency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Forfivo&trade; XL: Use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe hepatic cirrhosis: Use with extreme caution; maximum dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aplenzin&trade;: 174 mg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Buproban&reg;, Zyban&reg;: 150 mg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Forfivo&trade; XL: Use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Wellbutrin&reg;: 75 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Wellbutrin SR&reg;: 100 mg once daily or 150 mg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Wellbutrin XL&reg;: 150 mg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     The mean AUC increased by ~1.5-fold for hydroxybupropion and ~2.5-fold for erythro/threohydrobupropion; median T",
"     <sub>",
"      max",
"     </sub>",
"     was observed 19 hours later for hydroxybupropion, 31 hours later for erythro/threohydrobupropion; mean half-life for hydroxybupropion increased fivefold, and increased twofold for erythro/threohydrobupropion in patients with severe hepatic cirrhosis compared to healthy volunteers.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F143184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 75 mg [generic for Wellbutrin&reg;], 100 mg [generic for Wellbutrin&reg;]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Wellbutrin&reg;: 75 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as hydrobromide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aplenzin&trade;: 174 mg, 348 mg, 522 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as hydrochloride: 100 mg [generic for Wellbutrin SR&reg;], 150 mg [generic for Wellbutrin SR&reg;], 150 mg [generic for Wellbutrin XL&reg;], 150 mg [generic for Zyban&reg;], 200 mg [generic for Wellbutrin SR&reg;], 300 mg [generic for Wellbutrin XL&reg;]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Budeprion SR&reg;: 100 mg [contains tartrazine; generic for Wellbutrin SR&reg;]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Budeprion SR&reg;: 150 mg [generic for Wellbutrin SR&reg;]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Budeprion XL&reg;: 150 mg [DSC] [generic for Wellbutrin XL&reg;]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Budeprion XL&reg;: 300 mg [DSC] [contains tartrazine; generic for Wellbutrin XL&reg;]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Buproban&reg;: 150 mg [generic for Zyban&reg;]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Forfivo&trade; XL: 450 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Wellbutrin XL&reg;: 150 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, sustained release, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Wellbutrin SR&reg;: 100 mg, 150 mg, 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zyban&reg;: 150 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F143168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes bupropion hydrobromide tablet, extended release bupropion hydrochloride 450 mg tablet, sustained release hydrochloride tablet",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Aplenzin&trade;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085915.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085915.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Forfivo&trade; XL:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM280358.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM280358.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Wellbutrin&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089824.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089824.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Wellbutrin SR&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089826.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089826.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Wellbutrin XL&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM172744.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM172744.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Zyban&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089835.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089835.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F143189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals. Sustained release and extended release tablets (hydrochloride and hydrobromide salt formulations) should be swallowed whole; do not crush, chew, or divide. The insoluble shell of the extended-release tablet may remain intact during GI transit and is eliminated in the feces.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F143188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of major depressive disorder, including seasonal affective disorder (SAD); adjunct in smoking cessation (Buproban&reg;, Zyban&reg;)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F143238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Attention-deficit/hyperactivity disorder (ADHD); depression associated with bipolar disorder",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F143252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Aplenzin&trade; may be confused with Albenza&reg;, Relenza&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       BuPROPion may be confused with busPIRone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Forfivo&trade; XL may be confused with Forteo&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Wellbutrin XL&reg; may be confused with Wellbutrin SR&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zyban&reg; may be confused with Diovan&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F143240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequencies, when reported, reflect highest incidence reported with sustained release product.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Tachycardia (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (25% to 34%), insomnia (11% to 20%), dizziness (6% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (17% to 26%), weight loss (14% to 23%), nausea (1% to 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (3% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Palpitation (2% to 6%), arrhythmias (5%), chest pain (3% to 4%), hypertension (2% to 4%; may be severe), flushing (1% to 4%), hypotension (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Agitation (2% to 9%), confusion (8%), anxiety (5% to 7%), hostility (6%), nervousness (3% to 5%), sleep disturbance (4%), sensory disturbance (4%), migraine (1% to 4%), abnormal dreams (3%), irritability (2% to 3%), somnolence (2% to 3%), pain (2% to 3%), memory decreased (&le;3%), fever (1% to 2%), CNS stimulation (1% to 2%), depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (1% to 5%), pruritus (2% to 4%), urticaria (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Menstrual complaints (2% to 5%), hot flashes (1% to 3%), libido decreased (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation (5% to 10%), abdominal pain (2% to 9%), diarrhea (5% to 7%), flatulence (6%), anorexia (3% to 5%), appetite increased (4%), taste perversion (2% to 4%), vomiting (2% to 4%), dyspepsia (3%), dysphagia (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Polyuria (2% to 5%), urinary urgency (&le;2%), vaginal hemorrhage (&le;2%), UTI (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor (3% to 6%), myalgia (2% to 6%), weakness (2% to 4%), arthralgia (1% to 4%), arthritis (2%), akathisia (&le;2%), paresthesia (1% to 2%), twitching (1% to 2%), neck pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (2% to 3%), amblyopia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus (3% to 6%), auditory disturbance (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory infection (9%), cough increased (1% to 4%), sinusitis (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (8% to 9%), diaphoresis (5% to 6%), allergic reaction (including anaphylaxis, pruritus, urticaria)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Accommodation abnormality, aggression, akinesia, alopecia, amnesia, anaphylactic shock, anemia, angioedema, aphasia, ataxia, atrioventricular block, bronchospasm, bruxism, colitis, coma, coordination abnormal, cystitis, deafness, delayed hypersensitivity, delirium, delusions, depersonalization, derealization, diplopia, dysarthria, dyskinesia, dyspareunia, dysphoria, dystonia, dysuria, edema, EEG abnormality, emotional lability, erythema multiforme, esophagitis, euphoria, exfoliative dermatitis, extrapyramidal syndrome, extrasystoles, facial edema, gastric reflux, gastrointestinal hemorrhage, glossitis, glycosuria, gum hemorrhage, gynecomastia, hallucinations, hepatic damage, hepatitis, hirsutism, hyper-/hypoglycemia, hyper-/hypokinesia, hypertonia, hypoesthesia, hypomania, impotence, intestinal perforation, intraocular pressure increased, jaundice, leukocytosis, leukopenia, libido increased, liver function abnormal, lymphadenopathy, manic reaction, MI, muscle weakness, musculoskeletal chest pain, mydriasis, myoclonus, neuralgia, neuropathy, orthostatic hypotension, painful erection, pancreatitis, pancytopenia, paranoia, pneumonia, photosensitivity, pulmonary embolism, rhabdomyolysis, salpingitis, sciatica, seizures (dose-related), SIADH, stomach ulcer, Stevens-Johnson syndrome, stomatitis, stroke, suicidal ideation, syncope, tardive dyskinesia, thrombocytopenia, tongue edema, urinary incontinence, urinary retention, vasodilation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F143192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bupropion or any component of the formulation; seizure disorder; history of anorexia/bulimia; use of MAO inhibitors within 14 days; patients undergoing abrupt discontinuation of ethanol, benzodiazepines, barbiturates, or antiepileptics; patients receiving other dosage forms of bupropion",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Aplenzin&trade;: Additional contraindications: Other conditions that increase seizure risk, including arteriovenous malformation, severe head injury, severe stroke, CNS tumor, or CNS infection",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F143172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Major psychiatric warnings (use in treating psychiatric disorders):",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal thinking/behavior (use in treating psychiatric disorders):",
"     <b>",
"      [U.S. Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;",
"     </b>",
"     consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1-2 months of therapy or during periods of dosage adjustments (increases or decreases); the patient&rsquo;s family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription.",
"     <b>",
"      Bupropion is not FDA approved for use in children.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Patients treated with antidepressants should be observed for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS stimulation: May cause CNS stimulation (restlessness, anxiety, insomnia) or anorexia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cognitive impairment: May cause motor or cognitive impairment in some patients,  which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Anaphylactoid/anaphylactic reactions have occurred, with symptoms of pruritus, urticaria, angioedema, and dyspnea. Serious reactions have been (rarely) reported, including Stevens-Johnson syndrome and anaphylactic shock. Arthralgia, myalgia, and fever with rash and other symptoms suggestive of delayed hypersensitivity resembling serum sickness have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuropsychiatric effect (use in smoking cessation):",
"     <b>",
"      [U.S. Boxed Warning]: Serious neuropsychiatric events, including depression, suicidal thoughts, and suicide, have been reported with use;",
"     </b>",
"     some cases may have been complicated by symptoms of nicotine withdrawal following smoking cessation. Smoking cessation (with or without treatment) is associated with nicotine withdrawal symptoms and the exacerbation of underlying psychiatric illness; however, some of the behavioral disturbances were reported in treated patients who continued to smoke. Neuropsychiatric symptoms (eg, mood disturbances, psychosis, hostility) have occurred in patients with and without pre-existing psychiatric disease; many cases resolved following therapy discontinuation although in some cases, symptoms persisted. Monitor all patients for behavioral changes and psychiatric symptoms (eg, agitation, depression, suicidal behavior, suicidal ideation); inform patients to discontinue treatment and contact their healthcare provider immediately if they experience any behavioral and/or mood changes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Bupropion may cause a dose-related risk of seizures. Use is contraindicated in patients with a history of seizures or certain conditions with high seizure risk (eg, arteriovenous malformation, severe head injury, severe stroke, CNS tumor, CNS infection, history of anorexia/bulimia, or patients undergoing abrupt discontinuation of ethanol, benzodiazepines, barbiturates, or antiepileptic drugs). Use caution with concurrent use of antipsychotics, antidepressants, theophylline, systemic corticosteroids, stimulants (including cocaine), anorectants, or hypoglycemic agents, or with excessive use of ethanol, benzodiazepines, sedative/hypnotics, or opioids. Use with caution in seizure-potentiating metabolic disorders (hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia). The dose-dependent risk of seizures may be reduced by gradual dose increases and limiting the daily dose to bupropion hydrochloride &le;450 mg or bupropion hydrobromide &le;522 mg. Use of multiple bupropion formulations is contraindicated. Permanently discontinue if seizure occurs during therapy. Chewing, crushing, or dividing long-acting products may increase seizure risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sexual dysfunction: The incidence of sexual dysfunction with bupropion is generally lower than with SSRIs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Weight loss: May cause weight loss; use caution in patients where weight loss is not desirable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; ADHD (unlabeled use): All children diagnosed with ADHD who may be candidates for stimulant medications should have a thorough cardiovascular assessment to identify risk factors for sudden cardiac death prior to initiation of drug therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease, history of hypertension, or coronary artery disease; treatment-emergent hypertension (including some severe cases) has been reported, both with bupropion alone and in combination with nicotine transdermal systems.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; reduced dose and/or frequency recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mania/hypomania: May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder.",
"     <b>",
"      Bupropion is not FDA approved for bipolar depression.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; consider a reduction in dosing frequency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be at greater risk of accumulation during chronic dosing. Reduced dose recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extended release tablet: Insoluble tablet shell may remain intact and be visible in the stool.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electroconvulsive therapy (ECT): May increase the risks associated with electroconvulsive therapy (ECT); consider discontinuing, when possible, prior to ECT treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F143235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2A6 (minor), CYP2B6 (major), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F143177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the adverse/toxic effect of BuPROPion. Specifically, seizure threshold may be lowered. BuPROPion may enhance the adverse/toxic effect of Alcohol (Ethyl). Specifically, alcohol tolerance may decrease during treatment. Management: Patients receiving bupropion should be advised to minimize or avoid alcohol consumption due to possible lower alcohol tolerance, and lower seizure threshold associated with heavy alcohol consumption/abrupt discontinuation of heavy consumption.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.  Management: Initiate atomoxetine at a reduced dose (adult doses -- patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inducers (Strong): May increase the metabolism of CYP2B6 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Moderate): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Strong): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Strong) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of BuPROPion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P88 may be increased. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P95 may be decreased. CYP2D6 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: BuPROPion may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: May decrease the serum concentration of BuPROPion. Concentrations of the active metabolite, hydroxybupropion, may also be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lorcaserin: BuPROPion may enhance the serotonergic effect of Lorcaserin. This could result in serotonin syndrome.  Management: Seek alternatives to this combination when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the neurotoxic (central) effect of BuPROPion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: BuPROPion may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of BuPROPion. Management: Use bupropion with caution, and monitor for increased adverse effects, during and 2 weeks following discontinuation of mifepristone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quazepam: May increase the serum concentration of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May decrease the serum concentration of BuPROPion. Mixed effects on concentrations of the active hydroxybupropion metabolite have been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased.  Management: Tetrabenazine adult dose should be reduced by 50% when starting a strong CYP2D6 inhibitor.  Maximum tetrabenazine adult dose is 50 mg/day when used with a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: BuPROPion may decrease the metabolism of Tricyclic Antidepressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Amoxapine; Protriptyline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F143206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, SAMe, gotu kola, kava kava (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F143179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3062314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to adverse events observed in some animal studies, bupropion is classified as pregnancy category C. A significant increase in major teratogenic effects has not been observed following exposure to bupropion during pregnancy; however, the risk of spontaneous abortions may be increased (additional studies are needed to confirm). The long-term effects on development and behavior have not been studied.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Pregnancy itself does not provide protection against depression. The ACOG recommends that therapy with antidepressants during pregnancy be individualized and should incorporate the clinical expertise of the mental health clinician, obstetrician, primary care provider, and pediatrician. If treatment is needed, consider gradually stopping antidepressants 10-14 days before the expected date of delivery to prevent potential withdrawal symptoms in the infant. If this is done and the woman is considered to be at risk of relapse from her major depressive disorder, the medication can be restarted following delivery, although the dose should be readjusted to that required before pregnancy. Bupropion has also been evaluated for smoking cessation during pregnancy; current recommendations suggest that pharmacologic treatments be considered only after other therapies have failed. Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy (Yonkers, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F143221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates &ldquo;of concern&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F143195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bupropion and its metabolites are excreted into breast milk, although neither bupropion nor its metabolites have been detected in the plasma of breast-fed infants. Adverse events have not been reported in older breast-fed infants; however, a seizure was noted in one 6-month old infant (a causal effect could not be confirmed). In a study of 10 women, estimated infant exposure was 2% of the weight-adjusted maternal dose. Use caution and consider risks of discontinuing therapy in nursing mothers.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F143194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (Budeprion SR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $168.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (100): $181.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (Buproban Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (100): $181.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (BuPROPion HCl ER (Smoking Det) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (60): $116.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (BuPROPion HCl ER (SR) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $168.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (500): $966.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (60): $226.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (Wellbutrin SR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (60): $261.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (60): $279.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (60): $519.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (Zyban Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (60): $223.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Aplenzin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     174 mg (30): $239.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     348 mg (30): $315.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     522 mg (30): $718.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (BuPROPion HCl ER (XL) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (30): $156.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (30): $143.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Forfivo XL Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     450 mg (30): $162.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Wellbutrin XL Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (30): $289.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (30): $382.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (BuPROPion HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (100): $73.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $97.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Wellbutrin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (100): $266.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $354.85",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F143181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Body weight; mental status for depression, suicidal ideation (especially at the beginning of therapy or when doses are increased or decreased), anxiety, social functioning, mania, panic attacks; blood pressure (when used in conjunction with nicotine transdermal systems)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     When used for the treatment of ADHD, thoroughly evaluate for cardiovascular risk.   Monitor heart rate, blood pressure, and consider obtaining ECG prior to initiation (Vetter, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F143185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic levels (trough, 12 hours after last dose): 50-100 ng/mL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F143196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Betetrim (TW);",
"     </li>",
"     <li>",
"      Bupep SR (IN);",
"     </li>",
"     <li>",
"      Buprotrin (TW);",
"     </li>",
"     <li>",
"      Buxon (CN);",
"     </li>",
"     <li>",
"      Elontril (EE);",
"     </li>",
"     <li>",
"      Funnix (TW);",
"     </li>",
"     <li>",
"      Nicopion (KP);",
"     </li>",
"     <li>",
"      Odranal (AR, CO);",
"     </li>",
"     <li>",
"      Prewell (TW);",
"     </li>",
"     <li>",
"      Prexaton (AU);",
"     </li>",
"     <li>",
"      Quomen (TH);",
"     </li>",
"     <li>",
"      Wellbutrin (MX, PE, PY, TW, VE);",
"     </li>",
"     <li>",
"      Wellbutrin SR (AR, BB, BM, BS, CN, CR, DO, EC, GT, HK, HN, JM, KP, NI, PA, SG, SV, UY);",
"     </li>",
"     <li>",
"      Wellbutrin XL (BB, BM, BS, CO, CR, EC, GT, HN, JM, KP, PA, PE, TH, TW);",
"     </li>",
"     <li>",
"      Wellbutrin XR (IL);",
"     </li>",
"     <li>",
"      Zyban (AT, BB, BE, BG, BM, BR, BS, BZ, CH, CZ, DE, DK, FI, FR, GB, GR, GY, IE, IL, IN, IT, JM, MY, NL, NO, NZ, PL, PR, PT, SE, SR, TR, TT);",
"     </li>",
"     <li>",
"      Zyban LP (FR);",
"     </li>",
"     <li>",
"      Zyban SR (SG);",
"     </li>",
"     <li>",
"      Zyban Sustained Release (AU);",
"     </li>",
"     <li>",
"      Zylexx SR (PK);",
"     </li>",
"     <li>",
"      Zyntabac (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F143171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aminoketone antidepressant structurally different from all other marketed antidepressants; like other antidepressants the mechanism of bupropion's activity is not fully understood. Bupropion is a relatively weak inhibitor of the neuronal uptake of norepinephrine and dopamine, and does not inhibit monoamine oxidase or the reuptake of serotonin. Metabolite inhibits the reuptake of norepinephrine. The primary mechanism of action is thought to be dopaminergic and/or noradrenergic.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F143191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~20-47 L/kg (Laizure, 1985)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 84%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic via CYP2B6 to hydroxybupropion; non-CYP-mediated metabolism to  erythrohydrobupropion and threohydrobupropion. Metabolite activity ranges from 20% to 50% potency of bupropion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Distribution: 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elimination: ~14 hours (range: 8-24 hours); Metabolites: Hydroxybupropion: 20 &plusmn; 5 hours; Erythrohydrobupropion: 33 &plusmn; 10 hours; Threohydrobupropion: 37 &plusmn; 13 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extended release (Aplenzin&trade;): 21 &plusmn; 7 hours; Metabolites: Hydroxybupropion: 24 &plusmn; 5 hours; Erythrohydrobupropion: 31 &plusmn; 8 hours; Threohydrobupropion: 51 &plusmn; 9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bupropion: Immediate release: Within 2 hours; Sustained release: Within 3 hours; Extended release: ~5 hours (Forfivo&trade; XL: 5 hours [fasting]; 12 hours [fed])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metabolite: Hydroxybupropion: Immediate release: ~3 hours; Extended release, sustained release: ~6-7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (87%, primarily as metabolites); feces (10%, primarily as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, &ldquo;The Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26073/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;American Academy of Pediatrics Subcommittee on Attention-Deficit/Hyperactivity Disorder and Committee on Quality Improvement. Clinical Practice Guidelines: Treatment of the School-Aged Child With Attention-Deficit/Hyperactivity Disorder,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(4):1033-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26073/abstract-text/11581465/pubmed\" id=\"11581465\" target=\"_blank\">",
"        11581465",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Academy of Pediatrics/American Heart Association, &ldquo;Clarification of Statement on Cardiovascular Evaluation and Monitoring of Children and Adolescents With Heart Disease Receiving Medications for ADHD: May 16, 2008,&rdquo;",
"      <i>",
"       J Dev Behav Pediatr",
"      </i>",
"      , 2008, 29(4):335.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26073/abstract-text/18698199/pubmed\" id=\"18698199\" target=\"_blank\">",
"        18698199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barrickman LL, Petty PJ, Allen AJ, et al, &ldquo;Bupropion Versus Methylphenidate in the Treatment of Attention-Deficit Hyperactivity Disorder,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1995, 34(5):649-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26073/abstract-text/7775360/pubmed\" id=\"7775360\" target=\"_blank\">",
"        7775360",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Branconnier RJ, Cole JO, Ghazvinian S, et al, &ldquo;Clinical Pharmacology of Bupropion and Imipramine in Elderly Depressives,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1983, 44(5 Pt 2):130-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26073/abstract-text/6406441/pubmed\" id=\"6406441\" target=\"_blank\">",
"        6406441",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fiore M, Jaen CR, Baker TB, et al, &ldquo;A Clinical Practice Guideline for Treating Tobacco Use and Dependence: 2008 Update. A U.S. Public Health Service Report,&rdquo;",
"      <i>",
"       Am J Prev Med",
"      </i>",
"      , 2008,  35(2):158-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26073/abstract-text/18617085/pubmed\" id=\"18617085\" target=\"_blank\">",
"        18617085",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conners CK, Casat CD, Gualtieri CT, et al, &ldquo;Bupropion Hydrochloride in Attention Deficit Disorder With Hyperactivity,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1996, 35(10):1314-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26073/abstract-text/8885585/pubmed\" id=\"8885585\" target=\"_blank\">",
"        8885585",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davidson J, &ldquo;Seizures and Bupropion: A Review,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1989, 50(7):256-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26073/abstract-text/2500425/pubmed\" id=\"2500425\" target=\"_blank\">",
"        2500425",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fiore MC, Jaen CR, Baker TB, et al,",
"      <i>",
"       Treating Tobacco Use and Dependence: 2008 Update.",
"      </i>",
"      Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. May 2008. Available at",
"      <a href=\"file://www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf\" target=\"_blank\">",
"       file://www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf.",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fiore M, Jaen CR, Baker TB, et al, &ldquo;A Clinical Practice Guideline for Treating Tobacco Use and Dependence: 2008 Update. A U.S. Public Health Service Report,&rdquo;",
"      <i>",
"       Am J Prev Med",
"      </i>",
"      , 2008,  35(2):158-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26073/abstract-text/18617085/pubmed\" id=\"18617085\" target=\"_blank\">",
"        18617085",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hayes PE and Kristoff CA, &ldquo;Adverse Reactions to Five New Antidepressants,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1986, 5:471-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26073/abstract-text/3087684/pubmed\" id=\"3087684\" target=\"_blank\">",
"        3087684",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jennison TA, Brown P, Crossett J, et al, &ldquo;A High-Performance Liquid Chromatographic Method for Quantitating Bupropion in Human Plasma or Serum,&rdquo;",
"      <i>",
"       J Anal Toxicol",
"      </i>",
"      , 1995, 19(2):69-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26073/abstract-text/7769789/pubmed\" id=\"7769789\" target=\"_blank\">",
"        7769789",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kane JM, Cole K, Sarantakos S, et al, &ldquo;Safety and Efficacy of Bupropion in Elderly Patients: Preliminary Observations,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1983, 44(5 Pt 2):134-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26073/abstract-text/6406442/pubmed\" id=\"6406442\" target=\"_blank\">",
"        6406442",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kavoussi RJ, Segraves RT, Hughes AR, et al, &ldquo;Double-Blind Comparison of Bupropion Sustained Release and Sertraline in Depressed Outpatients,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1997, 58(12):532-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26073/abstract-text/9448656/pubmed\" id=\"9448656\" target=\"_blank\">",
"        9448656",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Laizure SC, DeVane CL, Stewart JT, et al, &ldquo;Pharmacokinetics of Bupropion and Its Major Basic Metabolites in Normal Subjects After a Single Dose,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1985, 38(5):586-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26073/abstract-text/3931955/pubmed\" id=\"3931955\" target=\"_blank\">",
"        3931955",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leverich GS, Altshuler LL, Frye MA, et al, &ldquo;Risk of Switch in Mood Polarity to Hypomania or Mania in Patients with Bipolar Depression During Acute and Continuation Trials of Venlafaxine, Sertraline, and Bupropion as Adjuncts to Mood Stabilizers,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2006, 163(2):232-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26073/abstract-text/16449476/pubmed\" id=\"16449476\" target=\"_blank\">",
"        16449476",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McIntyre RS, Mancini DA, McCann S, et al, &ldquo;Topiramate Versus Bupropion SR When Added to Mood Stabilizer Therapy fpr the Depressive Phase of Bipolar Disorder: A Preliminary Single-Blind Study,&rdquo;",
"      <i>",
"       Bipolar Disord",
"      </i>",
"      , 2002, 4(3):207-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26073/abstract-text/12180276/pubmed\" id=\"12180276\" target=\"_blank\">",
"        12180276",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health , &ldquo;Attention Deficit Hyperactivity Disorder, The NICE Guideline on Diagnosis and Management of ADHD in Children, Young People and Adults,&rdquo; National Clinical Practice Guideline Number 72, 2008:1-664. Available at  www.nice.org.uk/cg072",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nelson JC and Devanand DP, \"A Systematic Review and Meta-Analysis of Placebo-Controlled Antidepressant Studies in People With Depression and Dementia,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2011, 59(4):577-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26073/abstract-text/21453380/pubmed\" id=\"21453380\" target=\"_blank\">",
"        21453380",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nissen SE, &ldquo;ADHD Drugs and Cardiovascular Risk,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(14):1445-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26073/abstract-text/16549404/pubmed\" id=\"16549404\" target=\"_blank\">",
"        16549404",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nixon Al, Long WH, Puopolo PR, et al, &ldquo;Bupropion Metabolites Produce False-Positive Urine Amphetamine Results,",
"      <i>",
"       Clin Chem",
"      </i>",
"      , 1995, 41(6 Pt 1):955-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26073/abstract-text/7768026/pubmed\" id=\"7768026\" target=\"_blank\">",
"        7768026",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pass SE and Simpson RW, &ldquo;Discontinuation and Reinstitution of Medications During the Perioperative Period,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(9):899-912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26073/abstract-text/15156966/pubmed\" id=\"15156966\" target=\"_blank\">",
"        15156966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pliszka S, &ldquo;Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2007, 46(7):894-921.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26073/abstract-text/17581453/pubmed\" id=\"17581453\" target=\"_blank\">",
"        17581453",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rabins PV, Blacker D, Rovner BW, et al, &ldquo;American Psychiatric Association Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias. Second Edition,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2007, 164(12 Suppl):5-56.  Available at file://psychiatryonline.org/guidelines.aspx",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26073/abstract-text/18340692/pubmed\" id=\"18340692\" target=\"_blank\">",
"        18340692",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Riggs PD, Leon SL, Mikulich SK, et al, &ldquo;An Open Trial of Bupropion for ADHD in Adolescents With Substance Use Disorders and Conduct Disorder,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1998, 37(12):1271-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26073/abstract-text/9847499/pubmed\" id=\"9847499\" target=\"_blank\">",
"        9847499",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spencer T, Biederman J, Kerman K, et al, &ldquo;Desipramine Treatment of Children With Attention-Deficit Hyperactivity Disorder and Tic Disorder or Tourette's Syndrome,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1993, 32(2):354-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26073/abstract-text/8444765/pubmed\" id=\"8444765\" target=\"_blank\">",
"        8444765",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Turpeinen M, Koivuviita N, Tolonen A, et al,  &ldquo;Effect of Renal Impairment on the Pharmacokinetics of Bupropion and its Metabolites,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 2007, 64(2):165-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26073/abstract-text/17335546/pubmed\" id=\"17335546\" target=\"_blank\">",
"        17335546",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Wyck Fleet J, Manberg PJ, Miller LL, et al, &ldquo;Overview of Clinically Significant Adverse Reactions to Bupropion,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1983, 44(5 Pt 2):191-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26073/abstract-text/6406456/pubmed\" id=\"6406456\" target=\"_blank\">",
"        6406456",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vetter VL, Elia J, Erickson CH, et al,  &ldquo;Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Stimulant Drugs. A Scientific Statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2008, 117:2407-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26073/abstract-text/18427125/pubmed\" id=\"18427125\" target=\"_blank\">",
"        18427125",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilens TE, Prince JB, Spencer T, et al, &ldquo;An Open Trial of Bupropion for the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder and Bipolar Disorder,&rdquo;",
"      <i>",
"       Biol Psychiatry",
"      </i>",
"      , 2003, 54(1):9-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26073/abstract-text/12842303/pubmed\" id=\"12842303\" target=\"_blank\">",
"        12842303",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yonkers KA, Wisner KL, Stewart DE, et al, &ldquo;The Management of Depression During Pregnancy: A Report From the American Psychiatric Association and the American College of Obstetricians and Gynecologists,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2009, 114(3):703-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/29/26073/abstract-text/19701065/pubmed\" id=\"19701065\" target=\"_blank\">",
"        19701065",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9171 Version 51.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-820E8C5BBF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_29_26073=[""].join("\n");
var outline_f25_29_26073=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708639\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143210\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143211\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143242\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143215\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143229\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143216\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143217\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143218\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143184\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143168\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874410\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143189\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143188\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143238\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143252\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143240\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143192\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143172\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143235\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143177\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143206\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143179\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062314\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143221\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143195\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143194\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143181\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143185\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143196\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143171\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143191\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9171\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9171|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/7/17526?source=related_link\">",
"      Bupropion: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/11/39096?source=related_link\">",
"      Bupropion: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_29_26074="Age-related macular degeneration: Treatment and prevention";
var content_f25_29_26074=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Age-related macular degeneration: Treatment and prevention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/29/26074/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/29/26074/contributors\">",
"     Jorge G Arroyo, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/29/26074/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/29/26074/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/29/26074/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/29/26074/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/29/26074/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/29/26074/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visual impairment is a major health problem for older adults and has significant impact on functional status and quality of life. Visual impairment limits the ability to safely drive a car and is associated with increased rates of falls and hip fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The growing proportion of older people in the population underscores the importance of this problem. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3385?source=see_link\">",
"     \"Approach to the evaluation of older drivers\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22602?source=see_link\">",
"     \"Falls in older persons: Risk factors and patient evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Age-related macular degeneration (AMD) is the leading cause of adult blindness and severe visual impairment in industrialized countries [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/4\">",
"     4",
"    </a>",
"    ]. Other common causes of visual impairment in older adults are [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presbyopia",
"     </li>",
"     <li>",
"      Cataract",
"     </li>",
"     <li>",
"      Glaucoma",
"     </li>",
"     <li>",
"      Diabetic retinopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/19/2362?source=see_link\">",
"     \"Cataract in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15289?source=see_link\">",
"     \"Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/38/32362?source=see_link\">",
"     \"Prevention and treatment of diabetic retinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment and prevention of AMD will be reviewed here. Treatment varies with the type of AMD: dry (atrophic) or wet (neovascular or exudative). These terms are defined elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/52/6986?source=see_link&amp;anchor=H2#H2\">",
"     \"Age-related macular degeneration: Clinical presentation, etiology, and diagnosis\", section on 'Definition and classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The etiology and diagnosis of AMD and the use of anticoagulants, antiplatelet agents, and thrombolytic therapy in patients with AMD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/52/6986?source=see_link\">",
"     \"Age-related macular degeneration: Clinical presentation, etiology, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/44/7881?source=see_link\">",
"     \"Anticoagulant, antiplatelet, and fibrinolytic (thrombolytic) therapy in patients at high risk for ocular hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT OF DRY AMD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dry age-related macular degeneration (AMD) typically progresses slowly over many years and is less threatening to vision than wet AMD. Smoking may increase the risk of progression to advanced AMD. Thus, patients with AMD should be particularly encouraged to quit smoking. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/52/6986?source=see_link\">",
"     \"Age-related macular degeneration: Clinical presentation, etiology, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A significant number of patients with dry AMD develop wet AMD. A population study of patients with dry AMD reported development of wet AMD in 7.1 percent over five years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/8\">",
"     8",
"    </a>",
"    ]. A higher rate of progression (13 to 18 percent at three years) has been reported in patients with bilateral soft drusen, which represents more severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no proven effective treatment for dry AMD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/10\">",
"     10",
"    </a>",
"    ]. Antioxidants, zinc, and laser therapy have all been tried.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Antioxidant vitamins and zinc",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antioxidants have been hypothesized to prevent cellular damage in the retina by limiting the effects of free radicals produced in the process of light absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/11\">",
"     11",
"    </a>",
"    ]. The effects of vitamins C, E, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    , and the antioxidant mineral zinc, are variable in patients with AMD, depending upon the severity of disease.",
"   </p>",
"   <p>",
"    As an example, 3640 subjects (aged 55 to 80 years) in the Age-Related Eye Disease Study (AREDS) were evaluated and designated to be in the following categories [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Category one &mdash; no AMD",
"     </li>",
"     <li>",
"      Category two &mdash; mild or borderline dry AMD",
"     </li>",
"     <li>",
"      Category three &mdash; moderate dry AMD",
"     </li>",
"     <li>",
"      Category four &mdash; advanced dry AMD (geographic atrophy involving the macula) or wet AMD (choroidal neovascularization)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Participants were randomly assigned to one of four treatment groups: antioxidants (vitamin C 500 mg, vitamin E 400 IU,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    15 mg); zinc (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/53/15187?source=see_link\">",
"     zinc oxide",
"    </a>",
"    80 mg and cupric oxide 2 mg); antioxidants plus zinc; or placebo. During an average follow-up of 6.3 years, the following findings were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with no AMD (category one) or mild or borderline AMD (category two) did not benefit from antioxidant",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      zinc supplementation.",
"     </li>",
"     <li>",
"      Zinc plus antioxidants, compared with placebo, lowered the risk for progression to advanced AMD or visual acuity loss in the good eye (OR 0.66, 95% CI 0.47-0.91) in patients with moderate and advanced AMD (categories three and four). Zinc alone was also associated with a lower risk of progression (OR 0.71, CI 0.52-0.99). Specifically, patients with extensive intermediate size drusen, at least one large druse, or noncentral geographic atrophy in one or both eyes benefited from treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several other small trials of antioxidants for the treatment of AMD have been published, with inconsistent results. In a meta-analysis, 88 percent of patients were in the AREDS cohort, and the reviewers concluded that the other studies added little to the evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings suggest that patients with more extensive dry AMD may benefit from taking antioxidants and zinc at doses used in the AREDS trial. Eleven patients would need to be treated for seven years to prevent progression in one [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/12\">",
"     12",
"    </a>",
"    ]. If such treatment is given, patients should be aware of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"       Beta-carotene",
"      </a>",
"      supplementation has been linked to an increased risk of lung cancer, and this may be a particular issue in smokers. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8902?source=see_link&amp;anchor=H5#H5\">",
"       \"Chemoprevention of lung cancer\", section on 'Primary chemoprevention'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=see_link&amp;anchor=H9#H9\">",
"       \"Cigarette smoking and other risk factors for lung cancer\", section on 'Beta-carotene supplementation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"       Beta-carotene",
"      </a>",
"      supplementation may be associated with an increased risk of coronary heart disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26456?source=see_link\">",
"       \"Nutritional antioxidants in coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      High-dose vitamin E supplementation may increase all-cause mortality and the risk of heart failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link&amp;anchor=H26#H26\">",
"       \"Vitamin supplementation in disease prevention\", section on 'Vitamin E'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26456?source=see_link&amp;anchor=H9#H9\">",
"       \"Nutritional antioxidants in coronary heart disease\", section on 'Heart failure'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link&amp;anchor=H33#H33\">",
"       \"Vitamin supplementation in disease prevention\", section on 'All-cause mortality'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given these findings, it is reasonable to suggest treatment with the antioxidant vitamins A, C, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    , plus zinc, for nonsmokers with extensive intermediate size drusen, at least one large druse, or noncentral geographic atrophy in one or both eyes. We prefer treatment with the AREDS formula without beta-carotene in smokers, due to the increased risk of lung cancer with beta-carotene. Individual components of vitamins and zinc vary based on a given multivitamin preparation (",
"    <a class=\"external\" href=\"file://dietarysupplements.nlm.nih.gov/dietary/index.jsp\">",
"     file://dietarysupplements.nlm.nih.gov/dietary/index.jsp",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Ongoing trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AREDS2 trial is a large randomized multicenter clinical trial underway to evaluate whether lutein, zeaxanthin, or omega-3 fatty acids affect the course of nonexudative AMD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/14\">",
"     14",
"    </a>",
"    ]. Results from AREDS2 are anticipated in 2013.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Laser therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have investigated the efficacy of laser therapy for prevention of progression in people with high-risk drusen. While early randomized trials suggested that laser therapy produced a small improvement in visual acuity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/15-17\">",
"     15-17",
"    </a>",
"    ], subsequent trials showed increased rates of choroidal neovascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/18,19\">",
"     18,19",
"    </a>",
"    ] or no benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/20\">",
"     20",
"    </a>",
"    ]. A systematic review of nine randomized trials found that laser photocoagulation of drusen did not decrease the risk of choroidal revascularization, geographic atrophy, or loss of visual acuity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend that patients with dry AMD not be treated with laser therapy outside of clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT OF WET AMD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective specific therapies for exudative or wet AMD include intravitreous injection of a VEGF inhibitor, possibly thermal laser photocoagulation in selected patients, photodynamic therapy, and supplementation with zinc and antioxidant vitamins. The decision about specific therapies must take into account the likelihood of visual recovery, which is better with smaller, more recent lesions, as well as the risks of the various therapies.",
"   </p>",
"   <p>",
"    In general, our approach is as follows: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For nonsmokers, we suggest treatment with zinc and antioxidant vitamins. We suggest that smokers with wet AMD be treated with a daily vitamin supplement that contains zinc 80 mg (as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/53/15187?source=see_link\">",
"       zinc oxide",
"      </a>",
"      ) but does not contain",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      For patients who have acute foveal lesions, and for patients with later foveal lesions who do not have preserved vision in their second eye, we recommend intravitreal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/40/33413?source=see_link\">",
"       ranibizumab",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      . &nbsp;",
"     </li>",
"     <li>",
"      For patients with acute, large extrafoveal lesions or poorly-defined extrafoveal lesions, we also recommend treatment with intravitreal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/40/33413?source=see_link\">",
"       ranibizumab",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      .&nbsp;",
"     </li>",
"     <li>",
"      For patients with acute, small, well-defined, extrafoveal choroidal neovascularization lesions, we suggest treatment with thermal laser photocoagulation.",
"     </li>",
"     <li>",
"      For patients with nonacute lesions who have preserved vision in a second eye and who do not seem likely to achieve reading vision in the affected eye, we suggest photodynamic therapy, with or without intravitreal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/40/33413?source=see_link\">",
"       ranibizumab",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The efficacy and adverse effects of these therapies are reviewed below. (See",
"    <a class=\"local\" href=\"#H923348\">",
"     'Efficacy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H14057511\">",
"     'Adverse effects VEGF inhibitors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     VEGF inhibitors and inhibitor-like drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular endothelial growth factor (VEGF) is a potent mitogen and vascular permeability factor that plays a pivotal role in neovascularization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/52/6986?source=see_link&amp;anchor=H6#H6\">",
"     \"Age-related macular degeneration: Clinical presentation, etiology, and diagnosis\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of anti-VEGF molecules have been developed that may help limit the destructive effects of choroidal neovascular membranes in patients with AMD. One retrospective study found that a delay in the initiation of VEGF therapy (greater than 21 weeks compared with less than 7 weeks) after first symptoms of wet AMD was associated with poorer vision outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/22\">",
"     22",
"    </a>",
"    ]. Long-term cardiovascular effects of these medications in the treatment of AMD are unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of angiogenesis inhibitors\", section on 'Vascular endothelial growth factor'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although not demonstrated in clinical trials, observational data from",
"    <span class=\"nowrap\">",
"     Medicare/Medicaid",
"    </span>",
"    claims suggest a higher risk of stroke in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/40/33413?source=see_link\">",
"     ranibizumab",
"    </a>",
"    . Systemic levels are detectable after intravitreous injection of either ranibizumab or bevacizumab, which in theory might increase the risk of vascular events. Further studies are needed to determine if there is any increased risk, but clinicians should be aware of this concern when using VEGF inhibitors in patients who are at increased risk for hemorrhagic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14057511\">",
"     'Adverse effects VEGF inhibitors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H923348\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h4\">",
"     Ranibizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/40/33413?source=see_link\">",
"     Ranibizumab",
"    </a>",
"    is a recombinant humanized monoclonal antibody with specificity for VEGF [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Intravitreal ranibizumab is available for the treatment of wet AMD at a dose of 0.5 mg by intravitreal injection every month [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/27\">",
"     27",
"    </a>",
"    ]. Several randomized trials of patients with wet age-related macular degeneration (AMD) have shown benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/28-34\">",
"     28-34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The MARINA trial randomly assigned 716 patients with wet AMD to 24 monthly injections with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/40/33413?source=see_link\">",
"       ranibizumab",
"      </a>",
"      0.3 mg, ranibizumab 0.5 mg, or sham injection [",
"      <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/28\">",
"       28",
"      </a>",
"      ]. After one year, more patients treated with 0.3 mg or 0.5 mg ranibizumab lost fewer than 15 letters from baseline visual acuity (95 and 95 percent versus 62 percent with sham injection) and more patients treated with ranibizumab improved by at least 15 letters (25 and 34 percent versus 5 percent). There was also significant improvement in visual function in ranibizumab-treated patients, compared to a decline in sham-treated patients, as assessed by questionnaire at 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/29\">",
"       29",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The benefits were maintained at two years and confirmed with findings of decreased leakage with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"       fluorescein",
"      </a>",
"      angiography and decreased fibrosis on optical coherence tomography [",
"      <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/30\">",
"       30",
"      </a>",
"      ]. &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      The ANCHOR trial randomly assigned 423 patients with wet AMD to intravitreal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/40/33413?source=see_link\">",
"       ranibizumab",
"      </a>",
"      (0.3 mg or 0.5 mg) or photodynamic therapy (PDT) with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33060?source=see_link\">",
"       verteporfin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/31\">",
"       31",
"      </a>",
"      ]. After one year, more patients treated with 0.3 or 0.5 mg ranibizumab lost fewer than 15 letters of visual acuity (94 and 96 percent versus 64 percent with verteporfin) and more improved by at least 15 letters (36 and 40 percent versus 6 percent); outcomes were similar at two-year follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/32\">",
"       32",
"      </a>",
"      ]. Predictors of response to ranibizumab were better baseline visual acuity, smaller choroidal neovascularization lesion size, and younger patient age [",
"      <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h4\">",
"     Bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/40/33413?source=see_link\">",
"     ranibizumab",
"    </a>",
"    are closely-related antibodies. Ranibizumab is essentially an antibody fragment (Fab fragment) of bevacizumab with some modifications to the amino acid sequence that increase its binding of VEGF [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/35\">",
"     35",
"    </a>",
"    ]. Bevacizumab is approved in the United States as an intravenous infusion for the systemic therapy of colorectal cancer. Treatment with intravitreal bevacizumab for AMD is far less expensive than treatment with intravitreal ranibizumab ($50 compared to $1950 per injection) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Clinicians have used intravitreal injections of bevacizumab as a treatment for AMD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preliminary results from randomized trials comparing intravitreal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/40/33413?source=see_link\">",
"     ranibizumab",
"    </a>",
"    found no difference in visual acuity for the treatment of wet AMD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. As an example, in the Comparison of AMD Treatment Trial (CATT), 1208 patients with wet AMD were randomly assigned to monthly intravitreal injections of bevacizumab (1.25 mg) or ranibizumab (0.5 mg) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/40\">",
"     40",
"    </a>",
"    ]. At one-year follow-up, there was no difference in the primary outcome of mean change in visual acuity or in secondary outcomes, including visual acuity change of at least 15 letters or the change in fluid and foveal thickness on optical coherence tomography.",
"   </p>",
"   <p>",
"    Other smaller studies have also found intravitreal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    to be an effective treatment option [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. In a randomized trial of 131 patients with wet AMD, those randomly assigned to intravitreal bevacizumab (1.25 mg weekly for six weeks) were more likely to gain &ge;15 letters of visual acuity at 54 weeks compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/54/42851?source=see_link\">",
"     pegaptanib",
"    </a>",
"    sodium,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33060?source=see_link\">",
"     verteporfin",
"    </a>",
"    photodynamic therapy, or sham [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/43\">",
"     43",
"    </a>",
"    ]. A prospective case series in 60 patients with wet AMD reported that patients who received intravitreal bevacizumab (2.5 mg, with repeated injection at one and two months if optical coherence tomography or visual acuity results indicated ongoing disease activity) had significant improvement in mean visual acuity at 12 months, retinal anatomic improvement, and no ocular or systemic side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systemic administration of anti-VEGF medications such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    is also being studied in the treatment of AMD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Pegaptanib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravitreal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/54/42851?source=see_link\">",
"     pegaptanib",
"    </a>",
"    , the first VEGF inhibitor to be approved by the US Food and Drug Administration for the treatment of AMD, was studied in two randomized trials with a total of 1186 patients aged &ge;50 with subfoveal choroidal neovascularization secondary to AMD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/45\">",
"     45",
"    </a>",
"    ]. Compared with placebo, fewer patients treated with pegaptanib lost three or more lines of visual acuity (31 versus 45 percent). Ongoing benefits were seen in patients who were randomly assigned to continue pegaptanib for a second year [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/46\">",
"     46",
"    </a>",
"    ]. The benefit associated with pegaptanib in these trials was similar to that generally seen with photodynamic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/47\">",
"     47",
"    </a>",
"    ]. However, the clinical role of pegaptanib is uncertain given the apparently greater benefits and fewer side effects seen with the other intravitreal anti-VEGF medications. (See",
"    <a class=\"local\" href=\"#H14057511\">",
"     'Adverse effects VEGF inhibitors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1628685628\">",
"    <span class=\"h4\">",
"     Aflibercept",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/28/37312?source=see_link\">",
"     Aflibercept",
"    </a>",
"    , a protein that competes for binding of VEGF and therefore has an effect similar to VEGF inhibitors, is the most recent drug to be approved by the US Food and Drug Administration (FDA) for treating patients with wet AMD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/48\">",
"     48",
"    </a>",
"    ]. In two randomized trials of 2419 adult patients with wet AMD, intravitreal aflibercept (0.5 mg monthly, 2.0 mg monthly, or 2.0 mg every two months) was similarly effective in improving visual acuity at one year compared to intravitreal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/40/33413?source=see_link\">",
"     ranibizumab",
"    </a>",
"    0.5 mg monthly [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/49\">",
"     49",
"    </a>",
"    ]. Aflibercept has not been compared directly to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , which is less costly. Data from industry-sponsored clinical trials demonstrated that ocular adverse effects of aflibercept included eye pain, conjunctival hemorrhage, vitreous floaters, cataract formation, and elevated intraocular pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Treatment schedules for VEGF inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal frequency for injections of VEGF inhibitors is not known, although both the MARINA and ANCHOR trials evaluated monthly intravitreal injections. Current usual schedules of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/40/33413?source=see_link\">",
"     ranibizumab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    are monthly. Monthly injections potentially increase expense and may be poorly accepted by patients. The schedule for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    is to administer three doses (2 mg) at four week intervals, followed by 2 mg every eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several trials have evaluated less frequent or individualized dosing for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/40/33413?source=see_link\">",
"     ranibizumab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    . In the PIER trial, 184 patients with wet AMD were randomly assigned to intravitreal ranibizumab 0.3 mg, ranibizumab 0.5 mg, or sham injections monthly for three months and then quarterly with follow-up at 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/51\">",
"     51",
"    </a>",
"    ]. Patients in both treatment groups had significantly less decline in visual acuity than sham (-1.6 and -0.2 letters versus -16.3 letters for control). However, there was some visual loss comparing visual acuity at 3 and 12 months for the treatment groups, suggesting that some patients might have benefited from more frequent treatment. An observational study of patients treated with bevacizumab monthly for three months found that foveal thickening, which had improved during the course of treatment, worsened during the subsequent three months without treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An effective strategy would be individualized retreatment strategies, based upon regular patient follow-up with a combination of clinical examination for evidence of new hemorrhage, and optical coherence tomography (OCT) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    angiography for evidence of new leakage from reactivated choroidal neovascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/53\">",
"     53",
"    </a>",
"    ]. The Prospective Optical coherence tomography imaging of patients with Neovascular AMD Treated with intraocular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/40/33413?source=see_link\">",
"     ranibizumab",
"    </a>",
"    (PrONTO) study followed 40 patients for two years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/54\">",
"     54",
"    </a>",
"    ]. Patients received three monthly injections of ranibizumab and then were re-treated if monthly OCT revealed fluid; 43 percent of patients showed improvement of at least 15 letters with an average of 9.9 injections over two years. A similar study using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    showed equivalent improvement in VA at two years but fewer injections (average 4.9) were required, possibly related to more stringent criteria for reinjection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a longer half-life for bevacizumab [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/55\">",
"     55",
"    </a>",
"    ]. In a randomized trial comparing treatment with bevacizumab by a fixed-dose schedule, or dosing guided by OCT results, patients in the variable dosing group had equivalent visual improvement but received fewer injections (3.8 versus 9.5) over 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tachyphylaxis to VEGF inhibitors has been reported (affecting 2 percent in one series), and it is hypothesized that treatment schedules allowing intermittent rather than continuous cycles for injection might decrease the risk of tachyphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14057511\">",
"    <span class=\"h3\">",
"     Adverse effects VEGF inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The short-term adverse effects (ocular and nonocular) of intravitreal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/40/33413?source=see_link\">",
"     ranibizumab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    appear similar. Data on long-term adverse effects of the VEGF inhibitors are lacking. &nbsp;",
"   </p>",
"   <p>",
"    In the randomized trials described above, ocular adverse effects included endophthalmitis (1.0 to 1.3 percent) and serious uveitis (1.3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/30,32,43,45\">",
"     30,32,43,45",
"    </a>",
"    ]. Increases in intraocular pressure in the randomized trials were temporary, resolving within an hour of injection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/58\">",
"     58",
"    </a>",
"    ]. However, two small retrospective cohort studies showed an association between intravitreal anti-VEGF injections and increased risk for sustained intraocular pressure (IOP) elevation (occurring in 11.6 versus 5.3 percent of VEGF treated and controls, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Other ocular adverse effects that occurred more frequently than sham were: eye pain, floaters, punctate keratitis, cataracts, vitreous opacities, anterior chamber inflammation, vision disturbance, corneal edema, and ocular discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cardiovascular effects of these medications in the treatment of AMD are uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/23,61\">",
"     23,61",
"    </a>",
"    ]. In the SAILOR study of intravitreal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/40/33413?source=see_link\">",
"     ranibizumab",
"    </a>",
"    for wet AMD, stroke occurred in more patients treated with 0.5 mg compared to 0.3 mg of ranibizumab (1.2 versus 0.3 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/62\">",
"     62",
"    </a>",
"    ]. In subsequent pooled analysis of five trials, the risk for stroke was not significantly increased for patients treated with ranibizumab 0.3 mg versus control (OR 1.2, 95% CI 0.4-4.4) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/63\">",
"     63",
"    </a>",
"    ]. Patients treated with ranibizumab 0.5 mg versus control had a slightly increased risk for stroke (OR 2.2, 95% CI 0.8-7.1) that was not statistically significant. However, the stroke rate in both groups was lower than anticipated, and the clinical significance of the dose-related difference is uncertain.",
"   </p>",
"   <p>",
"    There are few studies comparing adverse effects among the VEGF inhibitors. In one randomized trial of 1208 patients comparing intravitreal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/40/33413?source=see_link\">",
"     ranibizumab",
"    </a>",
"    injections, the rate of serious adverse effects was significantly higher with bevacizumab than with ranibizumab (24 versus 19 percent), mostly due to hospitalizations for infections (eg, pneumonia and urinary tract infections) and gastrointestinal disorders (eg, bleeding and nausea and vomiting) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/40\">",
"     40",
"    </a>",
"    ]. Rates of stroke, myocardial infarction, and mortality were similar in both groups. It is inconclusive whether the greater rate of serious adverse effects of bevacizumab is clinically significant and a reflection of a true difference in risk. &nbsp;",
"   </p>",
"   <p>",
"    Further studies are needed to determine if there is any increased risk of stroke, but clinicians should be aware of this concern when using VEGF inhibitors in patients who are at increased risk for hemorrhagic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/24\">",
"     24",
"    </a>",
"    ]. In patients with increased risk for stroke, we suggest caution when considering treatment with VEGF inhibitors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Thermal laser photocoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thermal laser photocoagulation uses a relatively high intensity of thermal laser energy to coagulate the abnormal choroidal neovascular membrane. An adverse consequence of this treatment is focal damage to the overlying retina with the formation of a permanent blind spot. Thus, if used, this treatment should be limited to lesions outside of the central macula.",
"   </p>",
"   <p>",
"    A systematic review concluded that laser photocoagulation for choroidal neovascularization is no longer recommended, with the availability of newer pharmacologic therapies and the risk of scotomata and vision loss with photocoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Photodynamic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photodynamic therapy involves intravenous injection of the photosensitizing dye",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33060?source=see_link\">",
"     verteporfin",
"    </a>",
"    just prior to treatment with a photo-activating laser applied through the eye with a specific contact lens. The activated dye forms reactive free radicals that damage the vascular endothelium and result in thrombosis of the neovascular tissue that retains dye more avidly than normal vessels. However, these vessels often reopen [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. As an example, 33 percent of 108 eyes in one study showed evidence of recurrent choroidal neovascularization at 18 months following a course of photodynamic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/67\">",
"     67",
"    </a>",
"    ]. Re-treatment with photodynamic therapy is safe [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to anti-VEGF treatments, photodynamic therapy was primarily indicated in patients with a subfoveal neovascular membrane, in whom treatment with a conventional laser was contraindicated because of the iatrogenic scotoma. An analysis of two randomized trials (609 patients) and a subsequent systematic review of three trials (1022 patients) found that, compared with placebo, photodynamic therapy was associated with a lower rate of vision loss at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/65,70\">",
"     65,70",
"    </a>",
"    ]. Vision remained relatively stable over three years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24641334\">",
"    <span class=\"h2\">",
"     VEGF inhibitors with adjuvant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two techniques that cause vascular occlusion to the target tissue have been investigated for a role as adjuvant treatment to be used in combination with VEGF inhibition. Transpupillary thermotherapy (TTT) delivers radiation near the infrared spectrum through the pupil to the target tissue. At low doses (136",
"    <span class=\"nowrap\">",
"     mW/mm),",
"    </span>",
"    the surrounding neurosensory retina is not damaged. Photodynamic therapy is described above. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Photodynamic therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In a randomized trial, combined",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/40/33413?source=see_link\">",
"     ranibizumab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33060?source=see_link\">",
"     verteporfin",
"    </a>",
"    photodynamic therapy was more effective than photodynamic therapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/71\">",
"     71",
"    </a>",
"    ]. The combination of photodynamic therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    has been effective in case series, with randomized trials underway [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. Studies conflict on whether intravitreal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    in combination with photodynamic therapy provides added benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/75-78\">",
"     75-78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a randomized trial with a sham procedure as control, 100 patients were assigned to receive quarterly low-dose TTT or sham TTT for two years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/79\">",
"     79",
"    </a>",
"    ]. Patients in the TTT group required fewer treatments with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/40/33413?source=see_link\">",
"     ranibizumab",
"    </a>",
"    compared to those in the sham group (mean 8.0 versus 6.3 over two years). There was no difference in corrected visual acuity or lesion area between groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two types of surgical procedures have been tried without success for AMD, submacular surgery and macular translocation surgery:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Submacular surgery involves the removal of abnormal subretinal neovascularization and large submacular hemorrhages, if present. Clinical trials have been largely disappointing, showing lack of benefit and high rates of retinal detachment [",
"      <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/80-82\">",
"       80-82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Macular translocation surgery is experimental and involves moving the macula to a less diseased area of the retina in patients with subfoveal choroidal neovascularization [",
"      <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/83,84\">",
"       83,84",
"      </a>",
"      ]. The advent of effective pharmacologic therapy has limited the use of this surgical modality to patients with large submacular hemorrhages. The surgical risks are substantial (retinal detachment, proliferative vitreoretinopathy, diplopia) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;External beam radiation therapy has been studied in patients with AMD. A meta-analysis of randomized, controlled trials concluded that there was no consistent evidence of benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/86\">",
"     86",
"    </a>",
"    ]. The long-term safety of radiation therapy is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Zinc and antioxidant vitamins",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the Age-Related Eye Disease Study (AREDS) found a statistically significant benefit of antioxidants (vitamins C and E and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    ) plus zinc supplementation on progression of early AMD in one eye in patients with wet AMD or vision loss due to AMD in the other eye [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/12\">",
"     12",
"    </a>",
"    ]. We suggest treatment with supplements in these daily doses: vitamin C 500 mg, vitamin E 400 IU, beta-carotene 15 mg, zinc 80 mg (as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/53/15187?source=see_link\">",
"     zinc oxide",
"    </a>",
"    ), and copper 2 mg (as cupric oxide). Individual components of vitamins and zinc vary based on a given multivitamin preparation (",
"    <a class=\"external\" href=\"file://dietarysupplements.nlm.nih.gov/dietary/index.jsp\">",
"     file://dietarysupplements.nlm.nih.gov/dietary/index.jsp",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    supplementation has been linked to an increased risk of lung cancer and possibly to an increased risk of coronary heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/87\">",
"     87",
"    </a>",
"    ]. Therefore, in smokers, due to the increased risk of lung cancer, we suggest not supplementing with beta-carotene. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Antioxidant vitamins and zinc'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;An uncontrolled trial of intravitreal injections with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide (25 mg) found short term improvements in vision in two-thirds of treated eyes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/88\">",
"     88",
"    </a>",
"    ]. These results require confirmation in randomized trials. Intravitreal injection of triamcinolone is associated with glaucoma, cataract, and endophthalmitis.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     Triamcinolone",
"    </a>",
"    has also been injected into the posterior sub-Tenon's space for ARMD and other conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/89\">",
"     89",
"    </a>",
"    ]. The risks associated with this technique appear to be minimal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7606257\">",
"    <span class=\"h1\">",
"     VISUAL AIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have AMD may benefit from referral to low vision specialists and visual rehabilitation programs, as well as by use of a variety of visual aids for increasing reading ability and mobility. Tablet computers, such as the iPad, that allow for easy enlargement of the text and back lighting with excellent contrast of the letters, are often helpful. In our experience, the success of visual aids are directly correlated with the motivation of the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     FUTURE TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several investigational clinical trials are underway to evaluate treatment options for dry AMD. Potential new treatments include topical antioxidant eye drops, implantation of encapsulated human NTC cells, and fetal cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/90-92\">",
"     90-92",
"    </a>",
"    ]. The first report of transplantation of cells derived from human embryonic stem cells (hESCs) into human beings involved subretinal transplantation of cells differentiated to retinal pigment epithelium in a patient with dry AMD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/93\">",
"     93",
"    </a>",
"    ]. At four months there was no evidence of rejection, tumorigenicity, or ectopic tissue; there was minimal visual improvement although the patient had advanced disease at baseline. &nbsp;",
"   </p>",
"   <p>",
"    Ongoing trials for patients with neovascular AMD include evaluation of the angiogenesis inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    given as topical eye drops, subconjunctival injection of an antiproliferative polyamine analog (CGC-11047), and various combination treatment protocols that combine photodynamic therapy with intravitreal anti-VEGF agents [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/94-98\">",
"     94-98",
"    </a>",
"    ]. A topical kinase inhibitor with multiple growth factor targets, including VEGF, suppressed choroidal neovascularization in a mouse model [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic defects in various loci in the complement factor H gene can be found in over 50 percent of cases of macular degeneration. Gene-environment interactions compound the genetic risk for AMD and have been demonstrated for smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/100\">",
"     100",
"    </a>",
"    ] and for antibodies to C pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. Rapid and affordable genetic screening is being developed commercially, with the intent to identify high risk patients who could modify some risk factors or benefit from targeted therapy.",
"   </p>",
"   <p>",
"    Some genetic mutations associated with AMD are thought to result in increased complement activation and inflammation. The effects of anti-inflammatory drugs or vaccines on the progression of AMD are under investigation. Research trials include study of an intravitreal complement inhibitor (POT-4), vaccination with the immunomodulator copaxone, and treatment with anti-inflammatory agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    , and daclizumab) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whenever possible, patients should be encouraged to enroll in clinical trials of treatments for AMD. Information on clinical trials in the US is available at",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Healthy lifestyle habits may be helpful in preventing AMD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship of diet and the risk of AMD has been evaluated in a number of observational studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one cohort study, a healthy diet was associated with a lower risk of developing AMD after six years of follow-up, comparing the highest to lowest quintiles of healthy diet based on the modified 2005 Healthy Eating Index [",
"      <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/104\">",
"       104",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A reduction in the risk of AMD by consuming foods rich in carotenoids, particularly green leafy vegetables, vitamin C, vitamin E, and zinc has been found in some [",
"      <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/105,106\">",
"       105,106",
"      </a>",
"      ] but not all studies [",
"      <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/107,108\">",
"       107,108",
"      </a>",
"      ]. One study found that higher intake of carotenoids increased risk for AMD, even after controlling for cigarette smoking [",
"      <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/108\">",
"       108",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Blue Mountains Eye study found that high intake of vegetables and dietary lutein and zeaxanthin reduced the risk of AMD [",
"      <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/108\">",
"       108",
"      </a>",
"      ]. A case-control study involving AREDS participants found that dietary intake of lutein and zeaxanthin was inversely associated with neovascular AMD and geographic atrophy [",
"      <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/109\">",
"       109",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fish intake has been associated with a decreased risk of AMD [",
"      <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/110-114\">",
"       110-114",
"      </a>",
"      ]. In a study of AREDS participants with bilateral drusen, the risk of progression to central geographic atrophy was lower in patients reporting higher dietary intake of omega-3 fatty acids [",
"      <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/115\">",
"       115",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A longitudinal study in women aged 50 to 79 years found a direct association for dietary polyunsaturated fats and an inverse association for intake of monounsaturated fatty acids and prevalence of intermediate AMD [",
"      <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/116\">",
"       116",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given other apparent health benefits, it is reasonable to encourage a diet that includes fruits, vegetables, fish, and nuts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31641?source=see_link\">",
"     \"Healthy diet in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Nutritional and vitamin supplements",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, antioxidant vitamins and zinc may be of benefit in the treatment of selected patients with AMD (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Antioxidant vitamins and zinc'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H16\">",
"     'Zinc and antioxidant vitamins'",
"    </a>",
"    above). However, their role in prevention is unclear.",
"   </p>",
"   <p>",
"    Two meta-analyses including several prospective cohort studies and randomized trials did not find any beneficial effect of high antioxidant blood levels or supplementation with antioxidants (including dietary sources,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    , vitamins A, C, E, zinc) in reducing the risk of AMD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/117,118\">",
"     117,118",
"    </a>",
"    ]. A meta-analysis of four randomized trials similarly found no preventive effect for antioxidant supplements in general, or for beta-carotene or alpha-tocopheral specifically [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/119\">",
"     119",
"    </a>",
"    ]. The quality of the evidence was rated as high.",
"   </p>",
"   <p>",
"    In a randomized trial evaluating B vitamins, 5205 women at increased risk for cardiovascular disease without AMD at baseline were randomly assigned to B vitamins (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    2.5",
"    <span class=\"nowrap\">",
"     mg/d,",
"    </span>",
"    pyridoxine 50",
"    <span class=\"nowrap\">",
"     mg/d,",
"    </span>",
"    and cyanocobalamin 1",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/120\">",
"     120",
"    </a>",
"    ]. Women in the treatment arm had a reduced risk of developing AMD compared to the placebo group. At an average of 7.3 years follow-up, 55 women in the treatment group and 82 in the placebo group developed evidence of AMD (RR 0.66, 95% CI 0.47-0.93). This effect was demonstrable by two years. If these results are confirmed in other populations, vitamin B preparations may be a helpful intervention in the prevention of AMD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H168714590\">",
"    <span class=\"h2\">",
"     Physical activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one cohort study, physical activity was associated with a lower risk of developing AMD after six years of follow-up, comparing the highest to lowest quintile of physical activity measured in metabolic energy task hours per week [",
"    <a class=\"abstract\" href=\"UTD.htm?25/29/26074/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H136884288\">",
"    <span class=\"h2\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoking increases the risk of developing dry and wet AMD. The association of smoking and AMD is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/52/6986?source=see_link&amp;anchor=H11#H11\">",
"     \"Age-related macular degeneration: Clinical presentation, etiology, and diagnosis\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Smokers should be counseled to stop smoking, for prevention of AMD and other conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1482?source=see_link\">",
"     \"Cardiovascular risk of smoking and benefits of smoking cessation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/11/24754?source=see_link\">",
"       \"Patient information: Age-related macular degeneration (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that smokers be advised to immediately quit smoking, to prevent progression of AMD as well as other smoking-related illness (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H447888400\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that people without AMD should take antioxidants to prevent or delay the onset of this disease. However, given other apparent health benefits, we encourage a diet that includes fruits, green leafy vegetables, fish, and nuts. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Prevention'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Dry AMD treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that nonsmokers with extensive intermediate size drusen, at least one large druse, or noncentral geographic atrophy in one or both eyes be treated with daily oral supplements containing vitamin C 500 mg, vitamin E 400 IU,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      15 mg, zinc 80 mg (as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/53/15187?source=see_link\">",
"       zinc oxide",
"      </a>",
"      ), and copper 2 mg (as cupric oxide) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Antioxidant vitamins and zinc'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that smokers with extensive intermediate size drusen, at least one large druse, or noncentral geographic atrophy in one or both eyes be treated with a daily vitamin supplement that contains zinc 80 mg (as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/53/15187?source=see_link\">",
"       zinc oxide",
"      </a>",
"      ) but does not contain",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Antioxidant vitamins and zinc'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients may also wish to consider entering clinical trials of therapy aimed at slowing progression of AMD. In the US, information regarding available trials is available at",
"      <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"       www.clinicaltrials.gov",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Wet AMD treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with wet AMD in one eye, treatment with supplements may decrease progression to advanced AMD in the fellow eye:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that nonsmokers with wet AMD be treated with daily oral supplements containing vitamin C 500 mg, vitamin E 400 IU,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      15 mg, zinc 80 mg (as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/53/15187?source=see_link\">",
"       zinc oxide",
"      </a>",
"      ), and copper 2 mg (as cupric oxide) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Zinc and antioxidant vitamins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that smokers with wet AMD be treated with a daily vitamin supplement that contains zinc 80 mg (as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/53/15187?source=see_link\">",
"       zinc oxide",
"      </a>",
"      ) but does not contain",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Zinc and antioxidant vitamins'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Effective specific therapies for exudative or wet AMD are intravitreous injection of a VEGF inhibitor, possibly thermal laser photocoagulation (in selected patients), and photodynamic therapy. The decision about specific therapies must take into account the likelihood of visual recovery, which is greater with smaller, more recent lesions, as well as the risks of the various therapies. &nbsp;",
"   </p>",
"   <p>",
"    The following recommendations apply to active disease (leaking fluid, hemorrhage, or recent loss of vision):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients who have acute lesions involving the fovea, as well as in patients with later lesions involving the fovea who do not have preserved vision in their second eye, we recommend intravitreal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/40/33413?source=see_link\">",
"       ranibizumab",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'VEGF inhibitors and inhibitor-like drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with lesions that do not appear to be acute who have preserved vision in a second eye and who do not seem likely to achieve reading vision in the affected eye, we suggest photodynamic therapy, with or without intravitreal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/40/33413?source=see_link\">",
"       ranibizumab",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Photodynamic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with acute, small, well-defined extrafoveal lesions, we suggest treatment with thermal laser photocoagulation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Thermal laser photocoagulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with acute, large extrafoveal lesions or poorly-defined extrafoveal lesions, we recommend treatment with intravitreal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/40/33413?source=see_link\">",
"       ranibizumab",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'VEGF inhibitors and inhibitor-like drugs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/1\">",
"      Felson DT, Anderson JJ, Hannan MT, et al. Impaired vision and hip fracture. The Framingham Study. J Am Geriatr Soc 1989; 37:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/2\">",
"      Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/3\">",
"      Lord SR, Dayhew J. Visual risk factors for falls in older people. J Am Geriatr Soc 2001; 49:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/4\">",
"      Bressler NM. Age-related macular degeneration is the leading cause of blindness... JAMA 2004; 291:1900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/5\">",
"      Weih LM, VanNewkirk MR, McCarty CA, Taylor HR. Age-specific causes of bilateral visual impairment. Arch Ophthalmol 2000; 118:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/6\">",
"      Klaver CC, Wolfs RC, Vingerling JR, et al. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol 1998; 116:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/7\">",
"      Hyman L. Epidemiology of eye disease in the elderly. Eye (Lond) 1987; 1 ( Pt 2):330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/8\">",
"      Klein R, Klein BE, Jensen SC, Meuer SM. The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1997; 104:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/9\">",
"      Holz FG, Wolfensberger TJ, Piguet B, et al. Bilateral macular drusen in age-related macular degeneration. Prognosis and risk factors. Ophthalmology 1994; 101:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/10\">",
"      Arroyo JG. A 76-year-old man with macular degeneration. JAMA 2006; 295:2394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/11\">",
"      Christen WG, Glynn RJ, Hennekens CH. Antioxidants and age-related eye disease. Current and future perspectives. Ann Epidemiol 1996; 6:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/12\">",
"      Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001; 119:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/13\">",
"      Evans JR. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev 2006; :CD000254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/14\">",
"      Coleman H, Chew E. Nutritional supplementation in age-related macular degeneration. Curr Opin Ophthalmol 2007; 18:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/15\">",
"      Olk RJ, Friberg TR, Stickney KL, et al. Therapeutic benefits of infrared (810-nm) diode laser macular grid photocoagulation in prophylactic treatment of nonexudative age-related macular degeneration: two-year results of a randomized pilot study. Ophthalmology 1999; 106:2082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/16\">",
"      Ho AC, Maguire MG, Yoken J, et al. Laser-induced drusen reduction improves visual function at 1 year. Choroidal Neovascularization Prevention Trial Research Group. Ophthalmology 1999; 106:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/17\">",
"      Laser treatment in eyes with large drusen. Short-term effects seen in a pilot randomized clinical trial. Choroidal Neovascularization Prevention Trial Research Group. Ophthalmology 1998; 105:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/18\">",
"      Owens SL, Bunce C, Brannon AJ, et al. Prophylactic laser treatment hastens choroidal neovascularization in unilateral age-related maculopathy: final results of the drusen laser study. Am J Ophthalmol 2006; 141:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/19\">",
"      Friberg TR, Musch DC, Lim JI, et al. Prophylactic treatment of age-related macular degeneration report number 1: 810-nanometer laser to eyes with drusen. Unilaterally eligible patients. Ophthalmology 2006; 113:622.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/20\">",
"      Complications of Age-Related Macular Degeneration Prevention Trial Research Group. Laser treatment in patients with bilateral large drusen: the complications of age-related macular degeneration prevention trial. Ophthalmology 2006; 113:1974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/21\">",
"      Parodi MB, Virgili G, Evans JR. Laser treatment of drusen to prevent progression to advanced age-related macular degeneration. Cochrane Database Syst Rev 2009; :CD006537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/22\">",
"      Lim JH, Wickremasinghe SS, Xie J, et al. Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration. Am J Ophthalmol 2012; 153:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/23\">",
"      Wong TY, Liew G, Mitchell P. Clinical update: new treatments for age-related macular degeneration. Lancet 2007; 370:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/24\">",
"      Lim LS, Mitchell P, Seddon JM, et al. Age-related macular degeneration. Lancet 2012; 379:1728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/25\">",
"      van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA 2005; 293:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/26\">",
"      Folk JC, Stone EM. Ranibizumab therapy for neovascular age-related macular degeneration. N Engl J Med 2010; 363:1648.",
"     </a>",
"    </li>",
"    <li>",
"     www.lucentis.com (Accessed on January 12, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/28\">",
"      Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/29\">",
"      Chang TS, Bressler NM, Fine JT, et al. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 2007; 125:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/30\">",
"      Kaiser PK, Blodi BA, Shapiro H, et al. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007; 114:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/31\">",
"      Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/32\">",
"      Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009; 116:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/33\">",
"      Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 2007; 144:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/34\">",
"      Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 2010; 150:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/35\">",
"      Steinbrook R. The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 2006; 355:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/36\">",
"      Rosenfeld PJ. Intravitreal avastin: the low cost alternative to lucentis? Am J Ophthalmol 2006; 142:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/37\">",
"      Epstein P. Trials that matter: two faces of progress in the treatment of age-related macular degeneration. Ann Intern Med 2007; 146:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/38\">",
"      Brechner RJ, Rosenfeld PJ, Babish JD, Caplan S. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file. Am J Ophthalmol 2011; 151:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/39\">",
"      Subramanian ML, Ness S, Abedi G, et al. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial. Am J Ophthalmol 2009; 148:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/40\">",
"      CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/41\">",
"      Bashshur ZF, Haddad ZA, Schakal A, et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 2008; 145:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/42\">",
"      Goverdhan SV, Lochhead J. Submacular haemorrhages after intravitreal bevacizumab for large occult choroidal neovascularisation in age-related macular degeneration. Br J Ophthalmol 2008; 92:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/43\">",
"      Tufail A, Patel PJ, Egan C, et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ 2010; 340:c2459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/44\">",
"      Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 2006; 113:2002.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/45\">",
"      Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351:2805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/46\">",
"      VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, Chakravarthy U, Adamis AP, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006; 113:1508.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/47\">",
"      Ferris FL 3rd. A new treatment for ocular neovascularization. N Engl J Med 2004; 351:2863.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm280601.htm (Accessed on December 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/49\">",
"      Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012; 119:2537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/50\">",
"      Aflibercept (eylea) for age-related macular degeneration. Med Lett Drugs Ther 2012; 54:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/51\">",
"      Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008; 145:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/52\">",
"      Melamud A, Stinnett S, Fekrat S. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections. Am J Ophthalmol 2008; 146:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/53\">",
"      Brown DM, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 2007; 144:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/54\">",
"      Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009; 148:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/55\">",
"      Bashshur ZF, Haddad ZA, Schakal AR, et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study. Am J Ophthalmol 2009; 148:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/56\">",
"      El-Mollayess GM, Mahfoud Z, Schakal AR, et al. Fixed-interval versus OCT-guided variable dosing of intravitreal bevacizumab in the management of neovascular age-related macular degeneration: a 12-month randomized prospective study. Am J Ophthalmol 2012; 153:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/57\">",
"      Egh&oslash;j MS, S&oslash;rensen TL. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 2012; 96:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/58\">",
"      Schmidt-Erfurth U. Clinical safety of ranibizumab in age-related macular degeneration. Expert Opin Drug Saf 2010; 9:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/59\">",
"      Choi DY, Ortube MC, McCannel CA, et al. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib. Retina 2011; 31:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/60\">",
"      Hoang QV, Mendonca LS, Della Torre KE, et al. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology 2012; 119:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/61\">",
"      Campbell RJ, Gill SS, Bronskill SE, et al. Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study. BMJ 2012; 345:e4203.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/medwatch/safety/2007/safety07.htm#Lucentis (Accessed on January 12, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/63\">",
"      Bressler NM, Boyer DS, Williams DF, et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina 2012; 32:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/64\">",
"      Virgili G, Bini A. Laser photocoagulation for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2007; :CD004763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/65\">",
"      Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999; 117:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/66\">",
"      Arroyo JG, Michaud N, Jakobiec FA. Choroidal neovascular membranes treated with photodynamic therapy. Arch Ophthalmol 2003; 121:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/67\">",
"      Potter MJ, Szabo SM. Recurrence of choroidal neovascularisation after photodynamic therapy in patients with age-related macular degeneration. Br J Ophthalmol 2007; 91:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/68\">",
"      Blumenkranz MS, Bressler NM, Bressler SB, et al. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5. Arch Ophthalmol 2002; 120:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/69\">",
"      Blinder KJ, Bradley S, Bressler NM, et al. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 2003; 136:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/70\">",
"      Wormald R, Evans J, Smeeth L, Henshaw K. Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2007; :CD002030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/71\">",
"      Antoszyk AN, Tuomi L, Chung CY, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 2008; 145:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/72\">",
"      Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007; 114:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/73\">",
"      Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Graefes Arch Clin Exp Ophthalmol 2007; 245:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/74\">",
"      Kaiser PK, Registry of Visudyne AMD Therapy Writing Committee, Boyer DS, et al. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2009; 116:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/75\">",
"      Neovascular Age-Related Macular Degeneration, Periocular Corticosteroids, and Photodynamic Therapy (NAPP) Trial Research Group, Gilson MM, Bressler NM, et al. Periocular triamcinolone and photodynamic therapy for subfoveal choroidal neovascularization in age-related macular degeneration. Ophthalmology 2007; 114:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/76\">",
"      Chaudhary V, Mao A, Hooper PL, Sheidow TG. Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: a prospective randomized trial. Ophthalmology 2007; 114:2183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/77\">",
"      Piermarocchi S, Sartore M, Lo Giudice G, et al. Combination of photodynamic therapy and intraocular triamcinolone for exudative age-related macular degeneration and long-term chorioretinal macular atrophy. Arch Ophthalmol 2008; 126:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/78\">",
"      Kovacs KD, Quirk MT, Kinoshita T, et al. A retrospective analysis of triple combination therapy with intravitreal bevacizumab, posterior sub-tenon's triamcinolone acetonide, and low-fluence verteporfin photodynamic therapy in patients with neovascular age-related macular degeneration. Retina 2011; 31:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/79\">",
"      S&ouml;derberg AC, Algvere PV, Hengstler JC, et al. Combination therapy with low-dose transpupillary thermotherapy and intravitreal ranibizumab for neovascular age-related macular degeneration: a 24-month prospective randomised clinical study. Br J Ophthalmol 2012; 96:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/80\">",
"      Hawkins BS, Bressler NM, Miskala PH, et al. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings: SST report no. 11. Ophthalmology 2004; 111:1967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/81\">",
"      Bressler NM, Bressler SB, Childs AL, et al. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report no. 13. Ophthalmology 2004; 111:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/82\">",
"      Giansanti F, Eandi CM, Virgili G. Submacular surgery for choroidal neovascularisation secondary to age-related macular degeneration. Cochrane Database Syst Rev 2009; :CD006931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/83\">",
"      MacLaren RE, Bird AC, Sathia PJ, Aylward GW. Long-term results of submacular surgery combined with macular translocation of the retinal pigment epithelium in neovascular age-related macular degeneration. Ophthalmology 2005; 112:2081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/84\">",
"      Chen FK, Patel PJ, Uppal GS, et al. Long-term outcomes following full macular translocation surgery in neovascular age-related macular degeneration. Br J Ophthalmol 2010; 94:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/85\">",
"      Eandi CM, Giansanti F, Virgili G. Macular translocation for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2008; :CD006928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/86\">",
"      Sivagnanavel V, Evans JR, Ockrim Z, Chong V. Radiotherapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2004; :CD004004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/87\">",
"      Cort&eacute;s-Jofr&eacute; M, Rueda JR, Corsini-Mu&ntilde;oz G, et al. Drugs for preventing lung cancer in healthy people. Cochrane Database Syst Rev 2012; 10:CD002141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/88\">",
"      Jonas JB, Kreissig I, Hugger P, et al. Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol 2003; 87:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/89\">",
"      Cardillo JA, Melo LA Jr, Costa RA, et al. Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology 2005; 112:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/90\">",
"      Tanito M, Li F, Elliott MH, et al. Protective effect of TEMPOL derivatives against light-induced retinal damage in rats. Invest Ophthalmol Vis Sci 2007; 48:1900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/91\">",
"      Sieving PA, Caruso RC, Tao W, et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci U S A 2006; 103:3896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/92\">",
"      Radtke ND, Aramant RB, Seiler MJ, et al. Vision change after sheet transplant of fetal retina with retinal pigment epithelium to a patient with retinitis pigmentosa. Arch Ophthalmol 2004; 122:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/93\">",
"      Schwartz SD, Hubschman JP, Heilwell G, et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 2012; 379:713.",
"     </a>",
"    </li>",
"    <li>",
"     A Study to Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD. ClinicalTrials.gov Identifier: NCT00612456. Available at: file://clinicaltrials.gov/ct2/results?term=pazopanib+neovascular+AMD (Accessed on July 23, 2008).",
"    </li>",
"    <li>",
"     Safety Study of 16.5mg (3.3%) CGC-11047 Injected Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to Age Related Macular Degeneration. ClinicalTrials.gov Identifier: NCT00446654. Available at: file://clinicaltrials.gov/ct2/results?term=subconjunctival+injection+AND+CGC-11047 (Accessed on July 23, 2008).",
"    </li>",
"    <li>",
"     file://clinicaltrials.gov/ct2/results?term=anti-VEGF+AND+photodynamic+therapy (Accessed on July 23, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/97\">",
"      Arroyo JG. Towards a rational approach to combination therapy for neovascular age-related macular degeneration. Br J Ophthalmol 2007; 91:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/98\">",
"      Do DV. Antiangiogenic approaches to age-related macular degeneration in the future. Ophthalmology 2009; 116:S24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/99\">",
"      Doukas J, Mahesh S, Umeda N, et al. Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J Cell Physiol 2008; 216:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/100\">",
"      Scott WK, Schmidt S, Hauser MA, et al. Independent effects of complement factor H Y402H polymorphism and cigarette smoking on risk of age-related macular degeneration. Ophthalmology 2007; 114:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/101\">",
"      Kalayoglu MV, Bula D, Arroyo J, et al. Identification of Chlamydia pneumoniae within human choroidal neovascular membranes secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2005; 243:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/102\">",
"      Baird PN, Robman LD, Richardson AJ, et al. Gene-environment interaction in progression of AMD: the CFH gene, smoking and exposure to chronic infection. Hum Mol Genet 2008; 17:1299.",
"     </a>",
"    </li>",
"    <li>",
"     www.clinicaltrials.gov (Accessed on July 23, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/104\">",
"      Mares JA, Voland RP, Sondel SA, et al. Healthy lifestyles related to subsequent prevalence of age-related macular degeneration. Arch Ophthalmol 2011; 129:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/105\">",
"      Seddon JM, Ajani UA, Sperduto RD, et al. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group. JAMA 1994; 272:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/106\">",
"      van Leeuwen R, Boekhoorn S, Vingerling JR, et al. Dietary intake of antioxidants and risk of age-related macular degeneration. JAMA 2005; 294:3101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/107\">",
"      Cho E, Seddon JM, Rosner B, et al. Prospective study of intake of fruits, vegetables, vitamins, and carotenoids and risk of age-related maculopathy. Arch Ophthalmol 2004; 122:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/108\">",
"      Tan JS, Wang JJ, Flood V, et al. Dietary antioxidants and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Ophthalmology 2008; 115:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/109\">",
"      Age-Related Eye Disease Study Research Group, SanGiovanni JP, Chew EY, et al. The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS Report No. 22. Arch Ophthalmol 2007; 125:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/110\">",
"      Seddon JM, George S, Rosner B. Cigarette smoking, fish consumption, omega-3 fatty acid intake, and associations with age-related macular degeneration: the US Twin Study of Age-Related Macular Degeneration. Arch Ophthalmol 2006; 124:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/111\">",
"      Seddon JM, Cote J, Rosner B. Progression of age-related macular degeneration: association with dietary fat, transunsaturated fat, nuts, and fish intake. Arch Ophthalmol 2003; 121:1728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/112\">",
"      Chua B, Flood V, Rochtchina E, et al. Dietary fatty acids and the 5-year incidence of age-related maculopathy. Arch Ophthalmol 2006; 124:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/113\">",
"      Chong EW, Kreis AJ, Wong TY, et al. Dietary omega-3 fatty acid and fish intake in the primary prevention of age-related macular degeneration: a systematic review and meta-analysis. Arch Ophthalmol 2008; 126:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/114\">",
"      Christen WG, Schaumberg DA, Glynn RJ, Buring JE. Dietary &omega;-3 fatty acid and fish intake and incident age-related macular degeneration in women. Arch Ophthalmol 2011; 129:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/115\">",
"      SanGiovanni JP, Chew EY, Agr&oacute;n E, et al. The relationship of dietary omega-3 long-chain polyunsaturated fatty acid intake with incident age-related macular degeneration: AREDS report no. 23. Arch Ophthalmol 2008; 126:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/116\">",
"      Parekh N, Voland RP, Moeller SM, et al. Association between dietary fat intake and age-related macular degeneration in the Carotenoids in Age-Related Eye Disease Study (CAREDS): an ancillary study of the Women's Health Initiative. Arch Ophthalmol 2009; 127:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/117\">",
"      Evans JR, Henshaw K. Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. Cochrane Database Syst Rev 2008; :CD000253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/118\">",
"      Chong EW, Wong TY, Kreis AJ, et al. Dietary antioxidants and primary prevention of age related macular degeneration: systematic review and meta-analysis. BMJ 2007; 335:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/119\">",
"      Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. Cochrane Database Syst Rev 2012; 6:CD000253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/29/26074/abstract/120\">",
"      Christen WG, Glynn RJ, Chew EY, et al. Folic acid, pyridoxine, and cyanocobalamin combination treatment and age-related macular degeneration in women: the Women's Antioxidant and Folic Acid Cardiovascular Study. Arch Intern Med 2009; 169:335.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6912 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.167.4.114-2B3BC00349-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_29_26074=[""].join("\n");
var outline_f25_29_26074=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT OF DRY AMD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Antioxidant vitamins and zinc",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Ongoing trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Laser therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT OF WET AMD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      VEGF inhibitors and inhibitor-like drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H923348\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Ranibizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pegaptanib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1628685628\">",
"      Aflibercept",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Treatment schedules for VEGF inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14057511\">",
"      - Adverse effects VEGF inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Thermal laser photocoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Photodynamic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24641334\">",
"      VEGF inhibitors with adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Zinc and antioxidant vitamins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7606257\">",
"      VISUAL AIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      FUTURE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Nutritional and vitamin supplements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H168714590\">",
"      Physical activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H136884288\">",
"      Smoking",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H447888400\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Dry AMD treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Wet AMD treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/52/6986?source=related_link\">",
"      Age-related macular degeneration: Clinical presentation, etiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/44/7881?source=related_link\">",
"      Anticoagulant, antiplatelet, and fibrinolytic (thrombolytic) therapy in patients at high risk for ocular hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3385?source=related_link\">",
"      Approach to the evaluation of older drivers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1482?source=related_link\">",
"      Cardiovascular risk of smoking and benefits of smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/19/2362?source=related_link\">",
"      Cataract in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8902?source=related_link\">",
"      Chemoprevention of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=related_link\">",
"      Cigarette smoking and other risk factors for lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22602?source=related_link\">",
"      Falls in older persons: Risk factors and patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31641?source=related_link\">",
"      Healthy diet in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26456?source=related_link\">",
"      Nutritional antioxidants in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15289?source=related_link\">",
"      Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=related_link\">",
"      Overview of angiogenesis inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/11/24754?source=related_link\">",
"      Patient information: Age-related macular degeneration (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/38/32362?source=related_link\">",
"      Prevention and treatment of diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=related_link\">",
"      Vitamin supplementation in disease prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_29_26075="Low molecular weight heparins";
var content_f25_29_26075=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Low molecular weight heparins",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Generic name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Trade name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Manufacturer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enoxaparin",
"       </td>",
"       <td>",
"        Lovenox",
"       </td>",
"       <td>",
"        Sanofi-Aventis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dalteparin",
"       </td>",
"       <td>",
"        Fragmin",
"       </td>",
"       <td>",
"        Pfizer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tinzaparin*",
"       </td>",
"       <td>",
"        Innohep",
"       </td>",
"       <td>",
"        Leo Pharma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nadroparin&bull;",
"       </td>",
"       <td>",
"        Fraxiparine",
"       </td>",
"       <td>",
"        Glaxo Smith-Kline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Certoparin",
"       </td>",
"       <td>",
"        Sandoparin",
"       </td>",
"       <td>",
"        Sandoz Pharmaceuticals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reviparin",
"       </td>",
"       <td>",
"        Clivarin",
"       </td>",
"       <td>",
"        Abbott",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parnaparin",
"       </td>",
"       <td>",
"        Fluxum",
"       </td>",
"       <td>",
"        Opocrin",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Prepared by heparinase digestion. All others prepared by chemical depolymerization.",
"     <br>",
"      &bull; Ca salt. All others are sodium salt.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_29_26075=[""].join("\n");
var outline_f25_29_26075=null;
var title_f25_29_26076="Ventilation in DKA";
var content_f25_29_26076=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F50478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F50478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Compensatory hyperventilation in metabolic acidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 236px; height: 276px; background-image: url(data:image/gif;base64,R0lGODlh7AAUAaIAAP///wAAAP7+/gICAv39/QQEBQAAAAAAACH5BAAAAAAALAAAAADsABQBAAP/CLrc/jDKSau9OOvNu/9gKI5kaZ5oqq5s675wLM90bd94ru987//AoHBILBqPyKRyyWw6n9CodEqtWq/YrHbL7Xq/4LB4TC6bz+i0es1uu9/wuLwmmNvv+LweVwcQ9oAOAnUBgYF9CoWGiwCKjFyII45AAZOPHwEDlSCWPY6RlxuVo5xCnaEchaAdpz6rqBijm5hEr7AXsq2xRba3E72pvleFuaXCVcSyxkHAggDNhqoiukC2fXXQhwvZEtQ6zdcK3Hl9lZrLRQGD4hWzj5nw6D8Cmp3n3aTv7OMQ3jb0zx4gqrRqEEF+bugpo4UEGwODDwsyKsbQyLqHGLdl1BNJ/xHCfjIQgfIY4qOcUfc8+CPRa2U7h5FMnnEIzx0rHOoa8AM1wNkdiT5vxni1TubASeHwOEzJrmKLpDJ1amwkzuGhAfVIuBxRLkXSpnZgBlQWdcHWkokCBhTJwao0QzEbmStLFQbJolM9fL109EGunObe1nXRCSGhs6HiqlWbKZGiWYS20Z3g6E8HhQOgTU4TzlombPcadxUw1wTRxRhICxboq2vTw6EVpaS3V8VkzRg3l6FJWd2sTa7FMrtA+ljmtY6T/+5pdoFlrlR1V0UN4Th1PbmYMlgoF3jzjSFygh2coTPlULKygreA9Howqd3Rdjsmr62DwmZtpriLXLoX3f+IReCWWorpF5J7bZyWF3vQSeBfeRA8OAZeuKygoIQUgILhFl8hFGA3bOU23lPr/RTQPVaN82EEulgFA0AChtXAKFGtKJU6pymowmME6qNYO9NIJdyILfSEn4mShEcEMUHJ8eCKvG0oQmS13WHgexuEKKVT8NlhDnlYflDlDZGV6GUjxXGZYZdbZrkAc9S1OQVK4gmV2ndyopCnFKrZuB2EiWhYDWt7UjEZlDP66YJYhTpRTj4qxTgkmPEAAechNSkKpka2dAIpD2Uu0pOLdjbpYFqNnnpNnYFoUg9drQiaBEyanpFpfU3mpFiqu8BV12ax+jUqkfTlUI92ovzCznH/pCL4DywURcrajNMWCyqxGbiUprWmHIvrA5dy6woAx2rqUq1DeYcuGuauqQRtjE1UD6vJxtgEk8+EuwdKh9q7LpmLOPSctMrOCu28yGrgDUnvovdXKYy+VgWvTvwb6HXNGsqRs9kiqKsVGZ+UsMKyLijuPN1d2bHJ2C5hHcVNbGsuMCEzsRoe87Yr8SccI6ErzE2oh8kqFvPwFtBRRMzgfVnQ27IalmRMc1oP6XvyEH2aiSBvi1kjBc89c0ZWlxjHu82wXSfdgCZAsdFn1Fo3ZUmwaj86LNJCZE2si53ai/cJ2JQ2B91TD1QyyPcpPQfRrr4JKZWbiqPyEtvGHdY5/6rJlVx+nyJHtaOhmqhiMokwV+YpXRVNQ+VIRsiYKp9pPtbnYTMRIjntwPnbJDhafnUPj6I20KWfKcSAkZLyKTweX1odWOzcbZ5RzbZHQ1V7cZ7WmE9jVv90G9Fi29KCf7NQPhJCE/x7Gqqv/4IjOn+xKvM5xy8/7SfBM/LK7r8LtvpdOF/MlBSGgeQhfGGCBLV+gsB6gQFGIIkDAeynQAP9QW9soNO3sqAa6yymc2h4GwH/Y7x+tG+A36tQARdjtTdEL4H/+ZOXXujAFeIPDgxTExkEOI8GKox9vpvQrXQoBmY5qXYUOOGsqFeGZIDwh2vg4Q6cODkVhpBlIfxfqf/6ZxEkLs1tOHwi/9QgxSkGZoNjUOIT+ANAW3kRDD4coxnqMME3vI2CE2KH04CYpDa0cDfkoiEUr5i/9MGQi1gzgRoRCTit4DAhz+jXG8JVxhnc7o2RgxrZoshEpsVhkUcg1SWB1Doy0Ml0PfoiHDxohvQQZIsJMSIg07IaFTEyCekhzygF0p5KAmyO8+rkmATjy9XFq3sKJMqPJIMmTHYBHgZM5TNNxo1oStNWkPlcMU9wiufoSCPYg5p3mtNJKmRTMUyJ3raQmUdPyk8WBdASpLaXTXVCcocpO1JKZoGV422TDiP65w3csTtrigqL5STCq1gEP1WkMxSsNJX/asL/UMeV7iKgrOAu1/gdv4hHIe6owx9bJY2LREGDrttl6HzlHoHiAnPJY1lG25nCvN3JWTNN45xmd1MZCqMv96ofGvmSnyCaESUjLFbIqomTmibxZCnKykEkulNrAQOp1frbGYkIi2bR5Jxg0SpFuZqY5U2gcdecAZPw2JoKdKqK74sPWbu6NZ8l9Za86CNe0+HMCO7Vpns85F99EDtJDlYICIPVYYeAsKEu9pdBeqwPjDS2ST1Vsp6QC1pFpErMfuNmRu2oZ3MgtU3OZ7Se0I9JcoraU2XCkFj0a2ubSjV2yna2dKjfkUiJ23/oD4S27O24nMla4XqyRVY0rlobwZTV/yq3BkaC1+HO81y1bgJ1vaquDGDnjOBq90VC8lxnv9uCbLaRvF4hBVvRi4K1Opa90xCkHOGrpy8plr4Wim128ctN+L2Xv6JQ73oBzJAv/fexCSXgOHt6sWUiWAEDW8HzAhBPBiuAkqidbnsR9iGRHM2peC3UZjBKXpiVpU/l+ouKV8ziFrv4xTCOsYxnTOMZuwquwJNbXwl8qhK4lMf7MJ+9wGvJgv3YTWmrFpKnJScNcyq/YrBtaE0rPhDf1BoJbtCRlywgCTnYQhIRlG7Y0osts8ImgVuodLIDFvmqpBjhWMiYH5aR/X0tnPTUVIqKClQcM1g/BQXc9uSGZmSAVv92kIlKXGL3OumVoLngtFg54HQU8xqaFJ15oaLXkrlEOVpMjTahj4vqaT/f6zE8251Z35xKVZtgf6bWQAkT5WYouFpyqJbQlW4tH0Z35NCgBs5evGNm9ghtdyhK6wZmw08DT8miwZuwaV6ZnODpN4DX5jKUS7TRy8SpriHMciJdJ+TbSRlxqwb1l0cNlSfv2K3g5pCSo5xtQJmp2IsjVFiJfIwT31u87/4uOMDTthF5M8iRBHKPBSKcuOzFa+1W+IKqOOjYQlquEL7PceysXaCOKGHUG4kWSV1xAC8EKwIOjcrVGxvrAFo9mOM4ecmSPlVf1yYVb3apqRhr3FZaqoKJ2R2NtBObPO9cLocBss2DnpPZaIcg5zB6X27+afwuHSPI/sPLnxEYQrASq9AbKXovhMllxgRz+GbpeiIeU5YlXeLE6S6VzVpmK4997uvOy67MPeXnivvK5B4ygevuO8LLnapwT7ziF8/4xjv+8ZCPvOQnT/nKW/7ymM+85jfP+c57/vOgDz0OEgAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relationship between respiratory minute volume and arterial pH in patients with diabetic ketoacidosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from Kety, SS, Polis, BD, Nadler, CS, Schmidt, CF, J Clin Invest 1948; 27:500, by copyright permission of the American Society for Clinical Investigation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_29_26076=[""].join("\n");
var outline_f25_29_26076=null;
var title_f25_29_26077="Parenteral agents for moderate to severe foot infection";
var content_f25_29_26077=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Parenteral agents for empiric treatment of moderate to severe diabetic foot infections",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dosing (adult)*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Activity against Pseudomonas",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Beta-lactam/beta-lactamase inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ampicillin-sulbactam",
"       </td>",
"       <td>",
"        3 g every 6 hours",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Piperacillin-tazobactam",
"       </td>",
"       <td>",
"        4.5 g every 6 to 8 hours",
"       </td>",
"       <td>",
"        Yes, when dosed every 6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Carbapenems",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Imipenem-cilastatin",
"       </td>",
"       <td>",
"        500 mg every 6 hours",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Meropenem",
"       </td>",
"       <td>",
"        1 g every 8 hours",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ertapenem",
"       </td>",
"       <td>",
"        1 g every 24 hours",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Fluoroquinolones",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Moxifloxacin",
"       </td>",
"       <td>",
"        400 mg IV every 24 hours",
"       </td>",
"       <td>",
"        Yes",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Other regimens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Metronidazole PLUS one of the following:",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        500 mg IV every 8 hours",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Ceftriaxone",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 to 2 g every 24 hours",
"       </td>",
"       <td class=\"sublist_other\">",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Ceftazidime",
"       </td>",
"       <td class=\"sublist_other\">",
"        2 g every 8 to 12 hours",
"       </td>",
"       <td class=\"sublist_other\">",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Cefepime",
"       </td>",
"       <td class=\"sublist_other\">",
"        2 g every 12 hours",
"       </td>",
"       <td class=\"sublist_other\">",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Ciprofloxacin",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        400 mg IV every 8 to 12 hours",
"       </td>",
"       <td class=\"sublist_other\">",
"        Yes",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Levofloxacin",
"       </td>",
"       <td class=\"sublist_other\">",
"        750 mg IV every 24 hours",
"       </td>",
"       <td class=\"sublist_other\">",
"        Yes",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Aztreonam",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        2 g every 6 to 8 hours",
"       </td>",
"       <td class=\"sublist_other\">",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        PLUS one of the following if MRSA coverage is warranted",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vancomycin",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        15 to 20 mg/kg every 8 to 12 hours",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Linezolid",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        600 mg IV every 12 hours",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Daptomycin",
"       </td>",
"       <td>",
"        4 to 6 mg/kg every 24 hours",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Many of these agents require adjustment of the dose in the setting of renal dysfunction.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Empiric coverage for Pseudomonas aeruginosa may not be necessary except in severe cases or when the patient has particular risk for involvement with this organism, such as a macerated wound or one with significant water exposure.",
"     <br/>",
"     &Delta; Variable activity against Pseudomonas. Consult local susceptibility data before use.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     These agents should be used in combination with an agent that has good gram-positive coverage, such as Vancomycin, Linezolid, or Daptomycin.",
"     <br/>",
"     &sect; Maximum 2 grams per dose. Adjust dose to maintain vancomycin serum concentrations of 15 to 20 mg/dL. Total daily doses above &ge;4 g per day have been associated with increased risk of nephrotoxicity.",
"     <br/>",
"     &yen; Because of the toxicity associated with long-term Linezolid use, we do not recommend this agent for treatment of osteomyelitis.",
"    </div>",
"    <div class=\"reference\">",
"     Data courtesy of authors with additional data from: Lipsky BA, et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2012; 54:e132.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_29_26077=[""].join("\n");
var outline_f25_29_26077=null;
var title_f25_29_26078="Microscopy pediculosis nit1";
var content_f25_29_26078=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F65013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F65013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pediculosis - nits",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light microscopy shows nits on hair shafts. This specimen was taken from a patient with pediculosis capitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_29_26078=[""].join("\n");
var outline_f25_29_26078=null;
var title_f25_29_26079="Vascular malformation 9fg";
var content_f25_29_26079=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Right and left uterine angiograms",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 196px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Right (A) and left (B) uterine angiograms after uterine artery embolization reveal occlusions of both uterine arteries and their intrauterine branches (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_29_26079=[""].join("\n");
var outline_f25_29_26079=null;
